

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022700 A2

(51) International Patent Classification⁷: C12N

(21) International Application Number:
PCT/NZ2003/000199

(22) International Filing Date:
9 September 2003 (09.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/409,557 9 September 2002 (09.09.2002) US

(71) Applicants (for all designated States except US): **GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED** [NZ/NZ]; 1 Fox Street, Parnell, Auckland (NZ). **WRIGHTSON SEEDS LIMITED** [NZ/NZ]; Wrightson House, 14 Hartham Place, Porirua (NZ).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEMMER, Jeroen** [NL/NZ]; 317 Albany Highway, Albany, Auckland (NZ). **SHENK, Michael, Andrew** [US/NZ]; 83 a Te Awe Awe Street, Hokowhitu, Palmerston North (NZ). **HALL, Claire** [GB/NZ]; 3/253 Kapa Road, Mission Bay, Auckland (NZ). **FISH, Steven, A.** [GB/NZ]; 48 Gladstone Road, Parnell, Auckland (NZ).

(74) Agent: **BALDWIN SHELSTON WATERS**; P.O. Box 852, Wellington (NZ).

(81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished upon receipt of that report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTIFREEZE PROTEINS ISOLATED FROM FORAGE GRASSES AND METHODS FOR THEIR USE

(57) Abstract: Isolated polynucleotides encoding antifreeze polypeptides are provided, together with expression vectors and host cells comprising such isolated polynucleotides. Methods for the use of such polynucleotides and polypeptides are also provided.



WO 2004/022700 A2

ANTIFREEZE PROTEINS ISOLATED FROM FORAGE GRASSES
AND METHODS FOR THEIR USE

5 Reference to Related Applications

This application claims priority to U.S. Provisional Patent Application No. 60/409,557 filed September 9, 2002.

Technical Field of the Invention

10 This invention relates to polynucleotides isolated from forage grass tissues, specifically from *Lolium perenne* (perennial ryegrass) and *Festuca arundinacea* (tall fescue), as well as oligonucleotide probes and primers, genetic constructs comprising the polynucleotides, biological materials (including host cells and plants) incorporating the polynucleotides, polypeptides encoded by the polynucleotides, and methods for
15 using the polynucleotides and polypeptides. More particularly, the invention relates to antifreeze polypeptides involved in ice recrystallization pathways, and to polynucleotides encoding such polypeptides that confer freezing tolerance to plants.

Background of the Invention

20 Many organisms that inhabit environments where they are repeatedly exposed to freezing conditions have evolved specific antifreeze proteins (AFPs) that provide both freeze resistance and freeze tolerance (for review see Jia and Davies *Trends in Biochemical Science* 27:101-106, 2002). Significant potential exists to improve the survival of organisms, such as plants, by enhancing the expression of antifreeze proteins
25 or by introducing antifreeze proteins into organisms that are currently freeze-intolerant. Such methods would, for example, extend the range of climates in which forage crops and other commercially useful plants could be produced. Such methodology could also be applied to microorganisms in order to increase survival during recovery from cold temperatures, or may be employed in a similar fashion to improve survivability
30 associated with temperature fluctuations which occur during transportation at low temperatures.

Antifreeze proteins are found in a wide range of organisms including plants, fish, insects and bacteria. Although all AFPs are ice-binding proteins, there is a large variation in structure and amino acid sequence between organisms. For example, the

AFPs from fish are very different from those of plants. Even within different plant species there is little amino acid sequence homology between known AFP proteins, indicating that AFPs have evolved separately in a number of plant species. This structural diversity has made it difficult to identify functional domains in the AFP proteins, as well as to identify residues involved in the ice-protein interaction.

It has been proposed that AFPs bind to ice as a receptor-ligand interaction, with ice and AFPs being the ligand and receptor, respectively, to prevent further growth of the crystals. In certain freeze tolerant organisms, such as plants, the ice forms in the extra-cellular space. At several degrees below the melting point there is a tendency for ice to re-crystallize, with large crystals forming at the expense of smaller ones. These large crystals have the ability to irreparably damage cells. The main role of AFPs is therefore to slow or halt this re-crystallization process. Plant AFPs in particular tend to be good at inhibiting the ice re-crystallization process thereby lessening the damage caused by freezing. This contrasts with AFPs of Antarctic marine fish, which have an additional thermal hysteresis (TH) activity that reduces the freezing temperature of water inside the fish by controlling ice crystal growth.

Plant AFPs have been isolated from rye, perennial ryegrass and carrot. The carrot protein contains leucine-rich repeats and has some similarity with polygalacturonase inhibitor proteins (Worrall *et al.*, *Science* 282:115-117, 1998; Smallwood *et al.*, *Biochem. J.* 340:385-391, 1999). Over-expression of the carrot antifreeze protein in transgenic tobacco plants resulted in accumulation of this AFP in the apoplast. In ice re-crystallization experiments, the carrot protein inhibited the size of ice crystals formed. The TH activity of the carrot AFP was low; between 0.2 to 0.6 °C.

The perennial ryegrass AFP is rich in asparagine, valine and glycine residues and shares no sequence homology to the carrot AFP (WO 99/37782, Sidebottom *et al.*, *Nature* 406:256, 2000). The grass AFP has ice re-crystallization activity similar to that observed for the carrot AFP and has a low TH (0.2 – 0.45 °C). A theoretical three-dimensional structure has been developed for the grass AFP protein showing that it has a β -roll conformation (Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001). This gives the protein a long flat structure and presents two large flat surfaces for ice-binding. The physico-chemical characteristics of an AFP derived from *Lolium* have recently been investigated (Pudney *et al.*, *Archiv. Biochem. Biophys.* 410:238-245, 2003).

The scope for AFP applications extends from genetically modifying prokaryotic or eukaryotic organisms to produce formerly non-resident AFP proteins, into areas where AFPs are used as additives for cryoprotection. An example of this is molecular biology reagents such as restriction endonucleases, DNA modifying enzymes, DNA
5 polymerases and associated buffers which are sensitive to freeze thaw. Molecular biology reagents which are particularly sensitive to freezing, such as *in vitro* transcription/translation systems could potentially benefit by the presence of AFPs. Whole cells, such as preparations of *Escherichia coli*, yeasts, blood platelets, red blood cells, ova and sperm, in addition to multicellular complexes such as embryos and whole
10 organs, could be protected by the ice restructuring properties of AFPs.

AFP's may also be usefully employed in frozen food products where small crystalline structure is desirable, such as ice cream, and to provide a superior food quality upon thawing of frozen food products such as frozen fruit. For example, International Patent Publication WO 92/22581 describes the use of plant AFPs in
15 controlling ice crystal shape in ice cream. International Patent Publication WO 99/37782 describes the isolation of AFPs from grasses and the use of such AFPs in frozen food products, such as ice cream and frozen yogurt. A particularly attractive trait, which is exhibited by *Lolium* AFPs, is their stability at high temperature (Pudney *et al.*, *Archiv. Biochem. Biophys* 410:238-245, 2003). This lends itself to applications
20 within the food industry where high temperature treatments, such as pasteurization, are routinely used to inhibit microbial proliferation. AFPs may also be used in meat products to preserve texture and flavor after cold storage.

The ability to alter ice recrystallization may have wider applications within industrial crystallization processes. One example is separation, purification and
25 consistency in the production of pharmaceuticals, agrochemicals and pigments. AFPs could also be employed in the sugar industry where controlling crystal formation is highly desirable.

Another area where the manipulation of crystal architecture is desirable is in healthcare. AFPs could be localized in tumours where their propensity to form
30 hexagonal bipyramids would facilitate cellular damage. This type of treatment is particularly attractive because it is minimally invasive and does not have the accompanying negative side effects associated with traditional chemotherapy. Other healthcare applications include controlling the formation of biocrystals in disorders such as gout and in kidney stones.

It has been postulated that AFPs affect crystal formation by interfering with the molecular interactions between water molecules, see Jia and Davies, *Trends in Biochemical Science* 27:101-106, 2002. This could be used to assist the drying of, for example, dairy products or pharmaceuticals where a major component of process costs is incurred as part of the drying process.

Summary of the Invention

The present invention provides antifreeze proteins that are encoded by polynucleotides isolated from forage grass tissues. The polynucleotides were isolated from *Lolium perenne* (perennial ryegrass) and *Festuca arundinacea* (tall fescue) tissues taken at different times of the year, specifically in winter and spring, and from different parts of the plants, including: leaf blades, leaf base, pseudostems, roots and stems. The present invention also provides genetic constructs, expression vectors and host cells comprising the inventive polynucleotides, and methods for using the inventive polynucleotides and genetic constructs to modulate the cold tolerance of organisms, such as plants.

In specific embodiments, the isolated polynucleotides of the present invention comprise a sequence selected from the group consisting of: (a) SEQ ID NO: 1-12 and 25; (b) complements of SEQ ID NO: 1-12 and 25; (c) reverse complements of SEQ ID NO: 1-12 and 25; (d) reverse sequences of SEQ ID NO: 1-12 and 25; (e) sequences having a 99% probability of being functionally or evolutionarily related to a sequence of (a)-(d), determined as described below; and (f) sequences having at least 75%, 80%, 90%, 95% or 98% identity to a sequence of (a)-(d), the percentage identity being determined as described below. Polynucleotides comprising at least a specified number of contiguous residues ("x-mers") of any of SEQ ID NO: 1-12 and 25; and oligonucleotide probes and primers corresponding to SEQ ID NO: 1-12 and 25 are also provided. All of the above polynucleotides are referred to herein as "polynucleotides of the present invention."

In further aspects, the present invention provides isolated polypeptides encoded by the inventive polynucleotides. In specific embodiments, such polypeptides comprise an amino acid sequence of SEQ ID NO: 13-24 and 26. Polypeptides comprising a sequence having at least 75%, 80%, 90%, 95% or 98% identity to a sequence of SEQ ID NO: 13-24 and 26, wherein the polypeptide possesses the same functional activity as the polypeptide comprising a sequence of SEQ ID NO: 13-24 and 26 are also provided.

The present invention further contemplates isolated polypeptides comprising at least a functional portion of a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) SEQ ID NO: 13-24 and 26; and (b) sequences having at least 75%, 80%, 90%, 95% or 98% identity to a sequence of SEQ ID NO: 13-24 and 26.

5 In another aspect, the present invention provides genetic constructs comprising a polynucleotide of the present invention, either alone or in combination with one or more of the inventive sequences, or in combination with one or more known polynucleotides.

In addition, the present invention provides methods for the production of polypeptides derived from the inventive polynucleotides such that monomeric or
10 multimeric forms of the same or different polypeptides are generated. This type of construct has been identified as offering enhanced activity, see Baardnes *et al.*, *J. Biol. Chem.* in press, 2003, Miura *et al.*, *J. Biol. Chem.* 276: 1304-1310, 2001, and Nishimiya *et al.*, *J. Biol. Chem.* 278:32307-32312, 2003.

In certain embodiments, the present invention provides genetic constructs
15 comprising, in the 5'-3' direction: a gene promoter sequence; an open reading frame coding for at least a functional portion of a polypeptide of the present invention; and a gene termination sequence. An open reading frame may be orientated in either a sense or anti-sense direction. Genetic constructs comprising a non-coding region of a polynucleotide of the present invention or a polynucleotide complementary to a non-
20 coding region, together with a gene promoter sequence and a gene termination sequence, are also provided. Preferably, the gene promoter and termination sequences are functional in a host cell, such as a plant cell. Most preferably, the gene promoter and termination sequences are those of the original enzyme genes but others generally used in the art, such as the Cauliflower Mosaic Virus (CMV) promoter, with or without
25 enhancers, such as the Kozak sequence or Omega enhancer, and *Agrobacterium tumefaciens* nopaline synthase terminator may be usefully employed in the present invention. Tissue-specific promoters may be employed in order to target expression to one or more desired tissues. The construct may further include a marker for the identification of transformed cells.

30 In a further aspect, transgenic cells, such as transgenic plant cells, comprising the constructs of the present invention are provided, together with tissues and plants comprising such transgenic cells, and fruits, seeds and other products, derivatives, or progeny of such plants.

In yet another aspect, methods for modulating the cold tolerance of a target organism, such as a plant, are provided, such methods including stably incorporating into the genome of the target organism a genetic construct comprising a polynucleotide of the present invention. In a preferred embodiment, the target organism is a plant, preferably selected from the group consisting of commercially important trees and crop plants.

In a related aspect, a method for producing an organism or cell line, for example a prokaryotic or eukaryotic organism or cell line, such as a bacterium, yeast, mammalian cell line or plant, having increased cold tolerance is provided, the method comprising transforming a cell with a genetic construct comprising of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and mature growth.

In yet a further aspect, the present invention provides methods for modifying the activity of an antifreeze protein in a target organism, such as a plant, comprising stably incorporating into the genome of the target organism a genetic construct of the present invention.

The present invention further provides methods of cryopreserving cells, tissues or organisms, such methods comprising contacting the cell, tissue or organism to be preserved with a polypeptide of the present invention. Such cells, tissues and organisms may be selected, for example, from the group consisting of: mammals, plants, insects, fungi and bacteria.

In related applications molecular biology reagents, such as buffers, enzymes and *in vitro* protein synthesis systems, containing a polypeptide of the present invention are provided. Food additives comprising a polypeptide of the present invention are also provided, together with frozen food products comprising such food additives. In certain embodiments, such frozen food products are selected from the group consisting of: frozen fruit, frozen vegetables, ice cream, frozen yogurt, sherbet, sorbet, ice milk, water-ices, granites, frozen fruit purees and frozen meats. Preferably the amount of the inventive AFP within such products is from 0.00001 to 0.5%, by weight.

In another aspect, the inventive polypeptides may be employed as additives in industrial crystallization processes used in the separation and/or purification of compounds, or as components to improve consistency, for example, in pharmaceutical or agrochemical pigment production, or in the production of sugar and other crystalline materials. The polypeptides of the present invention may thus be usefully employed in

conjunction with known processes for the crystallization of sugar, such as those described in US Patents 4,216,025 and 5,286,298, and known processes for the production of pharmaceuticals, agrochemicals and pigments, such as that described in US Patent 6,506,886. The ability of a polypeptide of the present invention to directly
5 impact crystal formation in sucrose solutions has been demonstrated in a SPLAT ice-recrystallization assay, as described below in Example 3.

The inventive polypeptides may also be employed in therapeutic agents for the inhibition, disruption and/or restructuring of the crystal architecture within biocrystals associated with disorders such as gout and kidney stones. The inventive polypeptides
10 may also be introduced into unwanted tissue, such as tumors to promote cellular damage upon freezing when accompanied by a localized application of low temperature on or around the tumor site, as detailed, for example, in US Patent 5,654,279.

In addition, the inventive polypeptides may be employed in industrial or manufacturing processes to accelerate drying, such as in the production of foodstuffs
15 such as milk, and in the pharmaceutical industry where various drying technologies are used, for example freeze-drying and spray drying.

Brief Description of the Drawings

Fig. 1 shows the amino acid sequence of SEQ ID NO: 13, a *Lolium perenne*
20 antifreeze protein. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. A conserved lipoprotein membrane attachment site is in bold and italics, and conserved Cys-pairs identified N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant*
25 *Physiol.* 120:559-569, 1999) are double underlined.

Fig. 2 shows the amino acid sequence of SEQ ID NO: 14, a *Festuca arundinacea* antifreeze protein homolog. The signal sequence is underlined, the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed and
30 conserved Cys-pairs identified N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 3 shows the amino acid sequence of SEQ ID NO: 15, a *Lolium perenne* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid

sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 4 shows the amino acid sequence of SEQ ID NO: 16, a *Festuca arundinacea* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 5 shows the amino acid sequence of SEQ ID NO: 17, a *Lolium perenne* antifreeze protein homolog. The signal sequence is underlined, the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed and a conserved lipoprotein membrane attachment site is in bold and italics. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 6 shows the amino acid sequence of SEQ ID NO: 18, a *Festuca arundinacea* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed and a conserved lipoprotein membrane attachment site is in bold and italics. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 7 shows the amino acid sequence of SEQ ID NO: 19, a *Lolium perenne* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid

sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs
5 found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 8 shows the amino acid sequence of SEQ ID NO: 20, a *Lolium perenne* antifreeze protein homolog. The signal sequence and transmembrane domain are underlined, and the 7-amino acid sequence repeat region identified in antifreeze
10 proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. A conserved lipoprotein membrane attachment site is in bold and italics. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van
15 der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 9 shows the amino acid sequence of SEQ ID NO: 21, a *Festuca arundinacea* antifreeze protein homolog. The signal sequence and transmembrane domain are underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.*
20 81:3560-3565, 2001) is boxed. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined. A conserved lipoprotein membrane attachment site is in
25 bold and italics.

Fig. 10 shows the amino acid sequence of SEQ ID NO: 22, a *Lolium perenne* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. Conserved
30 leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 11 shows the amino acid sequence of SEQ ID NO: 23, a *Festuca arundinacea* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed.

5 Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

Fig. 12 shows the amino acid sequence of SEQ ID NO: 24, a *Lolium perenne* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs

10 found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

15

Fig. 13 shows the amino acid sequence of SEQ ID NO: 26, a *Lolium perenne* antifreeze protein homolog. The signal sequence is underlined, and the 7-amino acid sequence repeat region identified in antifreeze proteins (Sidebottom *et al.*, *Nature* 406:256, 2000; Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001) is boxed. Conserved leucine-rich repeats are in bold and underlined (Worrall *et al.*, *Science* 282:115-117, 1998) and cysteine-pairs with the conserved amino acid sequence of cysteine pairs found N-terminal of leucine-rich repeats of receptor-like kinases (Van der Knaap *et al.*, *Plant Physiol.* 120:559-569, 1999) are double underlined.

20

25

Detailed Description of the Invention

The polypeptides of the present invention, and the polynucleotides encoding the polypeptides, have activity in cold tolerance and anti-freeze pathways in plants. Using the methods and materials of the present invention, the cold tolerance of a plant may be

30 modulated by modulating expression of polynucleotides of the present invention, or by modifying the polynucleotides or the polypeptides encoded by such polynucleotides. The isolated polynucleotides and polypeptides of the present invention may thus be usefully employed in improving cold tolerance in any plant, thereby improving its performance and extending the range of climates in which it may be grown.

The cold tolerance of an organism, such as a plant, may be modified by incorporating additional copies of polynucleotides encoding the inventive anti-freeze proteins into the genome of the target organism. In addition, cold or freezing tolerance of mammalian, plant, insect, bacteria, archaea and fungal cells or tissues may be modified by incorporating additional copies of the inventive polynucleotides into the genome of the cells or tissues. The polynucleotides introduced may be in monomeric or multimeric form, composed of repeat units of the same specified polynucleotide or in combination with any of the other inventive polynucleotide sequences. The polypeptides encoded by the inventive anti-freeze protein polynucleotides can also be usefully employed in the cryopreservation of mammalian, plant, insect, bacteria, archaea and fungal cells or tissues.

Plant AFPs have demonstrated ice restructuring activity (Hon *et al.*, *Plant Physiol.* 109:879-889, 1995; Sidebottom *et al.*, *Nature* 406:256, 2000 and Pudney *et al.*, *Arch. Biochem. Biophys.* 410:238-245, 2003), which can be enhanced by generating multimeric forms, see Baardnes *et al.*, *J. Biol. Chem.* in press, 2003, and Nishimiya *et al.*, *J. Biol. Chem.* 278:32307-32312, 2003. The polypeptides of the present invention, used either individually, in multiples thereof or as engineered polypeptides consisting of individual or multiple units of the same or different inventive polypeptides, may be employed to modify crystallization processes. Applications within healthcare relate to cryosurgery, as described, for example, in US Patent 5,654,279 and the modification of biocrystals such as those associated with gout and kidney stones. In food, the inventive polypeptides have applications in maintaining flavor and texture, by offsetting the damage caused by the formation of large ice crystals. Their ability to change the structure of ice cream, for example, permits a lower level of fat incorporation while maintaining a desirable consistency. This has the health benefits of reducing fat content and therefore generating a product with a lower calorific value per gram weight.

Alternatively the polypeptides of the present invention, used either individually, in multiples thereof or as engineered polypeptides consisting of individual or multiple units of the same or different inventive polypeptides, may be usefully employed in manufacturing processes which use a crystallization process to purify, separate, or maintain consistency, by controlling the size and/or rate of crystal formation. This has useful application in the pharmaceutical, agrochemical and pigment industries, and may also be employed in the food industry where the propagation of regular crystals is desirable, for example in the production of sugar.

Jia and Davies (*Trends in Biochemical Science* 27:101-106, 2002) have indicated that AFP mechanisms involve hydrogen, Van der Waals and hydrophobic interactions. As demonstrated below, the inventive polypeptides, used either individually, in multiples thereof or as engineered polypeptides consisting of individual
5 or multiple units of the same or different inventive polypeptides, may be employed in drying processes to increase the rate of dehydration.

In one aspect, the present invention provides methods for modulating the cold tolerance of an organism, such methods involving stably incorporating into the genome of the organism a genetic construct comprising one or more polynucleotides of the
10 present invention. In related aspects, methods for producing an organism having an altered genotype or phenotype is provided, such methods comprising transforming a cell with a genetic construct of the present invention to provide a transgenic cell, and cultivating the transgenic cell under conditions conducive to regeneration and mature growth. Organisms, such as plants, having an altered genotype or phenotype as a
15 consequence of modulation of the level or content of a polynucleotide or polypeptide of the present invention compared to a wild-type organism, as well as components (seeds, etc.) of such organisms, and the progeny of such organisms, are contemplated by and encompassed within the present invention.

Target cells which may be usefully transformed with the genetic constructs of
20 the present invention include plant, mammalian, insect, fungal, archaea and bacterial cells. In one embodiment, the target organism is a plant species, preferably a cold sensitive plant, such as a cold sensitive tree or cold sensitive crop plant. Examples of cold sensitive trees include eucalyptus species. Examples of cold sensitive crop plants include rice, sugarcane and tropical fruit and vegetable plants. Other plants that may be
25 usefully transformed with the inventive genetic constructs include herbs, ornamental shrubs and flowering plants.

Additionally, the polynucleotide sequences identified as SEQ ID NOS: 1-12 and
25 and their variants, may be used to design oligonucleotide probes and primers. Oligonucleotide probes and primers have sequences that are substantially
30 complementary to the polynucleotide of interest over a certain portion of the polynucleotide. Oligonucleotide probes designed using the polynucleotides of the present invention may be employed to detect the presence and examine the expression patterns of genes in any organism having sufficiently similar DNA and RNA sequences in their cells using techniques that are well known in the art, such as slot blot DNA

hybridization techniques. Oligonucleotide primers designed using the polynucleotides of the present invention may be used for PCR amplifications. Oligonucleotide probes and primers designed using the polynucleotides of the present invention may also be used in connection with various microarray technologies, including the microarray
5 technology of Affymetrix Inc. (Santa Clara, CA).

In a first aspect, the present invention provides isolated polynucleotide sequences identified in the attached Sequence Listing as SEQ ID NO: 1-12 and 25, and polypeptide sequences identified in the attached Sequence Listing as SEQ ID NO: 13-24 and 26. The polynucleotides and polypeptides of the present invention have
10 demonstrated similarity to the following antifreeze proteins:

TABLE 1

SEQ ID NO: DNA	SEQ ID NO: polypeptide	Description
1	13	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 1.
2	14	Homologue isolated from <i>Festuca arundinacea</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 2.
3	15	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 3.
4	16	Homologue isolated from <i>Festuca arundinacea</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 4.
5	17	Homolog isolated from <i>Lolium perenne</i> of an antifreeze protein that are involved in inhibition of ice crystal

SEQ ID NO: DNA	SEQ ID NO: polypeptide	Description
		growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 5
6	18	Homologue isolated from <i>Festuca arundinacea</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 6
7	19	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 7
8	20	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 8
9	21	Homologue isolated from <i>Festuca arundinacea</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 9.
10	22	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 10.
11	23	Homologue isolated from <i>Festuca arundinacea</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 11.
12	24	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid

SEQ ID NO: DNA	SEQ ID NO: polypeptide	Description
		sequence and conserved domains are shown in Fig. 12.
25	26	Homologue isolated from <i>Lolium perenne</i> of an antifreeze protein that is involved in inhibition of ice crystal growth in plants. In the amino acid sequence, a 7-amino acid repeat (X X N X V X G) was identified (Kuiper <i>et al.</i> , <i>Biophys. J.</i> 81:3560-3565, 2001). The amino acid sequence and conserved domains are shown in Fig. 13.

As used herein, the term "antifreeze protein" refers to proteins that possess an ability to inhibit, or alter the growth of ice crystals. As discussed above, these proteins bind to ice crystals thereby inhibiting their growth, and enabling some plants and organisms to survive under freezing conditions (Kuiper *et al.*, *Biophys. J.* 81:3560-3565, 2001). The antifreeze proteins are generally hydrophilic and are high in asparagine, valine, serine, and threonine residues (Sidebottom *et al.*, *Nature* 406:256, 2000).

All the polynucleotides and polypeptides provided by the present invention are isolated and purified, as those terms are commonly used in the art. Preferably, the polypeptides and polynucleotides are at least about 80% pure, more preferably at least about 90% pure, and most preferably at least about 99% pure.

The word "polynucleotide(s)," as used herein, means a polymeric collection of nucleotides, and includes DNA and corresponding RNA molecules and both single and double stranded molecules, including HnRNA and mRNA molecules, sense and anti-sense strands of DNA and RNA molecules, and comprehends cDNA, genomic DNA, and wholly or partially synthesized polynucleotides. A polynucleotide of the present invention may be an entire gene, or any portion thereof. As used herein, a "gene" is a DNA sequence which codes for a functional protein or RNA molecule. Operable anti-sense polynucleotides may comprise a fragment of the corresponding polynucleotide, and the definition of "polynucleotide" therefore includes all operable anti-sense fragments. Anti-sense polynucleotides and techniques involving anti-sense polynucleotides are well known in the art and are described, for example, in Robinson-Benion *et al.*, *Methods in Enzymol.* 254(23): 363-375, 1995 and Kawasaki *et al.*, *Artific. Organs* 20(8): 836-848, 1996.

In specific embodiments, the present invention provides isolated polynucleotides comprising a sequence of SEQ ID NO: 1-12 or 25; polynucleotides comprising variants of SEQ ID NO: 1-12 or 25; polynucleotides comprising extended sequences of SEQ ID NO: 1-12 or 25 and their variants, oligonucleotide primers and
5 probes corresponding to the sequences set out in SEQ ID NO: 1-12 or 25 and their variants, polynucleotides comprising at least a specified number of contiguous residues of any of SEQ ID NO: 1-12 or 25 (*x*-mers), and polynucleotides comprising extended sequences which include portions of the sequences set out in SEQ ID NO: 1-12 and 25, all of which are referred to herein, collectively, as "polynucleotides of the present
10 invention." Polynucleotides that comprise complements of such polynucleotide sequences, reverse complements of such polynucleotide sequences, or reverse sequences of such polynucleotide sequences, together with variants of such sequences, are also provided.

The definition of the terms "complement(s)," "reverse complement(s)," and
15 "reverse sequence(s)," as used herein, is best illustrated by the following example. For the sequence 5' AGGACC 3', the complement, reverse complement, and reverse sequence are as follows:

complement	3' TCCTGG 5'
reverse complement	3' GGTCCT 5'
20 reverse sequence	5' CCAGGA 3'.

Preferably, sequences that are complements of a specifically recited polynucleotide sequence are complementary over the entire length of the specific polynucleotide sequence.

As used herein, the term "*x*-mer," with reference to a specific value of "*x*,"
25 refers to a polynucleotide comprising at least a specified number ("*x*") of contiguous residues of: any of the polynucleotides provided in SEQ ID NO: 1-12 and 25. The value of *x* may be from about 20 to about 600, depending upon the specific sequence.

Polynucleotides of the present invention comprehend polynucleotides comprising at least a specified number of contiguous residues (*x*-mers) of any of the
30 polynucleotides identified as SEQ ID NO: 1-12 and 25, or their variants. Similarly, polypeptides of the present invention comprehend polypeptides comprising at least a specified number of contiguous residues (*x*-mers) of any of the polypeptides identified as SEQ ID NO: 13-24 and 26. According to preferred embodiments, the value of *x* is at least 20, more preferably at least 40, more preferably yet at least 60, and most

preferably at least 80. Thus, polynucleotides of the present invention include polynucleotides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer, a 250-mer; or a 300-mer, 400-mer, 500-mer or 600-mer of a polynucleotide provided in SEQ ID NO: 1-12 and 25, or a variant of one
5 of the polynucleotides corresponding to the polynucleotides provided in SEQ ID NO: 1-12 and 25. Polypeptides of the present invention include polypeptides comprising a 20-mer, a 40-mer, a 60-mer, an 80-mer, a 100-mer, a 120-mer, a 150-mer, a 180-mer, a 220-mer, a 250-mer; or a 300-mer, 400-mer, 500-mer or 600-mer of a polypeptide provided in SEQ ID NO: 13-24 and 26, or a variant thereof.

10 Polynucleotides of the present invention were isolated by high throughput sequencing of cDNA libraries comprising forage grass tissue collected from *Lolium perenne* and *Festuca arundinacea*. Some of the polynucleotides of the present invention may be "partial" sequences, in that they do not represent a full-length gene encoding a full-length polypeptide. Such partial sequences may be extended by
15 analyzing and sequencing various DNA libraries using primers and/or probes and well known hybridization and/or PCR techniques. Partial sequences may be extended until an open reading frame encoding a polypeptide, a full-length polynucleotide and/or gene capable of expressing a polypeptide, or another useful portion of the genome is identified. Such extended sequences, including full-length polynucleotides and genes,
20 are described as "corresponding to" a sequence identified as one of the sequences of SEQ ID NO: 1-12 and 25 or a variant thereof, or a portion of one of the sequences of SEQ ID NO: 1-12 and 25 or a variant thereof, when the extended polynucleotide comprises an identified sequence or its variant, or an identified contiguous portion (x-mer) of one of the sequences of SEQ ID NOS: 1-12 and 25 or a variant thereof.
25 Similarly, RNA sequences, reverse sequences, complementary sequences, anti-sense sequences and the like, corresponding to the polynucleotides of the present invention, may be routinely ascertained and obtained using the cDNA sequences identified as SEQ ID NOS: 1-12 and 25.

The polynucleotides identified as SEQ ID NOS: 1-12 and 25 contain open
30 reading frames ("ORFs") encoding polypeptides and functional portions of polypeptides. Additionally, open reading frames encoding polypeptides may be identified in extended or full length sequences corresponding to the sequences set out as SEQ ID NOS: 1-12 and 25. Open reading frames may be identified using techniques that are well known in the art. These techniques include, for example, analysis for the

location of known start and stop codons, most likely reading frame identification based on codon frequencies, etc. Suitable tools and software for ORF analysis are well known in the art and include, for example, GeneWise, available from The Sanger Center, Wellcome Trust Genome Campus, Hinxton, Cambridge, CB10 1SA, United Kingdom; 5 Diogenes, available from Computational Biology Centers, University of Minnesota, Academic Health Center, UMHG Box 43, Minneapolis MN 55455; and GRAIL, available from the Informatics Group, Oak Ridge National Laboratories, Oak Ridge, Tennessee TN. Once a partial open reading frame is identified, the polynucleotide may be extended in the area of the partial open reading frame using techniques that are well 10 known in the art until the polynucleotide for the full open reading frame is identified.

Once open reading frames are identified in the polynucleotides of the present invention, the open reading frames may be isolated and/or synthesized. Expressible genetic constructs comprising the open reading frames and suitable promoters, initiators, terminators, etc., which are well known in the art, may then be constructed. 15 Such genetic constructs may be introduced into a host cell to express the polypeptide encoded by the open reading frame. Suitable host cells may include various prokaryotic and eukaryotic cells, including plant cells, mammalian cells, archaeal cells, bacterial cells, algae and the like.

The polynucleotides of the present invention may be isolated by high throughput 20 sequencing of cDNA libraries prepared from forage grass tissue, as described below in Example 1. Alternatively, oligonucleotide probes and primers based on the sequences provided in SEQ ID NOS: 1-12 and 25 can be synthesized as detailed below, and used to identify positive clones in either cDNA or genomic DNA libraries from forage grass tissue cells by means of hybridization or polymerase chain reaction (PCR) techniques. 25 Hybridization and PCR techniques suitable for use with such oligonucleotide probes are well known in the art (*see, for example, Mullis et al., Cold Spring Harbor Symp. Quant. Biol.*, 51:263, 1987; Erlich, ed., *PCR technology*, Stockton Press: NY, 1989; and Sambrook *et al.*, eds., *Molecular cloning: a laboratory manual*, 2nd ed., CSHL Press: Cold Spring Harbor, NY, 1989). In addition to DNA-DNA hybridization, DNA-RNA 30 or RNA-RNA hybridization assays are also possible. In the first case, the mRNA from expressed genes would then be detected instead of genomic DNA or cDNA derived from mRNA of the sample. In the second case, RNA probes could be used. Artificial analogs of DNA hybridizing specifically to target sequences could also be employed.

Positive clones can be analyzed by using restriction enzyme digestion, DNA sequencing or the like.

The polynucleotides of the present invention may also, or alternatively, be synthesized using techniques that are well known in the art. The polynucleotides may be synthesized, for example, using automated oligonucleotide synthesizers (e.g., Beckman Oligo 1000M DNA Synthesizer; Beckman Coulter Ltd., Fullerton, CA) to obtain polynucleotide segments of up to 50 or more nucleic acids. A plurality of such polynucleotide segments may then be ligated using standard DNA manipulation techniques that are well known in the art of molecular biology. One conventional and exemplary polynucleotide synthesis technique involves synthesis of a single stranded polynucleotide segment having, for example, 80 nucleic acids, and hybridizing that segment to a synthesized complementary 85 nucleic acid segment to produce a 5 nucleotide overhang. The next segment may then be synthesized in a similar fashion, with a 5 nucleotide overhang on the opposite strand. The "sticky" ends ensure proper ligation when the two portions are hybridized. In this way, a complete polynucleotide of the present invention may be synthesized entirely *in vitro*.

Oligonucleotide probes and primers complementary to and/or corresponding to SEQ ID NOS: 1-12 and 25 and variants of those sequences, are also comprehended by the present invention. Such oligonucleotide probes and primers are substantially complementary to the polynucleotide of interest over a certain portion of the polynucleotide. An oligonucleotide probe or primer is described as "corresponding to" a polynucleotide of the present invention, including one of the sequences set out as SEQ ID NOS: 1-12 and 25 or a variant thereof, if the oligonucleotide probe or primer, or its complement, is contained within one of the sequences set out as SEQ ID NOS: 1-12 and 25 or a variant of one of the specified sequences.

Two single stranded sequences are said to be substantially complementary when the nucleotides of one strand, optimally aligned and compared, with the appropriate nucleotide insertions and/or deletions, pair with at least 80%, preferably at least 90% to 95%, and more preferably at least 98% to 100%, of the nucleotides of the other strand. Alternatively, substantial complementarity exists when a first DNA strand will selectively hybridize to a second DNA strand under stringent hybridization conditions.

In specific embodiments, the oligonucleotide probes and/or primers comprise at least about 6 contiguous residues, more preferably at least about 10 contiguous residues, and most preferably at least about 20 contiguous residues complementary to a

polynucleotide sequence of the present invention. Probes and primers of the present invention may be from about 8 to 100 base pairs in length, preferably from about 10 to 50 base pairs in length, and more preferably from about 15 to 40 base pairs in length. The probes can be easily selected using procedures well known in the art, taking into
5 account DNA-DNA hybridization stringencies, annealing and melting temperatures, potential for formation of loops, and other factors that are well known in the art. Preferred techniques for designing PCR primers are disclosed in Dieffenbach and Dyksler, *PCR Primer: a laboratory manual*, CSHL Press: Cold Spring Harbor, NY, 1995. A software program suitable for designing probes, and especially for designing
10 PCR primers, is available from Premier Biosoft International, 3786 Corina Way, Palo Alto, CA 94303-4504.

The isolated polynucleotides of the present invention also have utility in genome mapping, in physical mapping, and in positional cloning of genes.

The polynucleotides identified as SEQ ID NOS: 1-12 and 25 were isolated from
15 cDNA clones and represent sequences that are expressed in the tissue from which the cDNA was prepared. RNA sequences, reverse sequences, complementary sequences, anti-sense sequences, and the like, corresponding to the polynucleotides of the present invention, may be routinely ascertained and obtained using the cDNA sequences identified as SEQ ID NOS: 1-12 and 25.

20 Identification of genomic DNA and heterologous species DNA can be accomplished by standard DNA/DNA hybridization techniques, under appropriately stringent conditions, using all or part of a polynucleotide sequence as a probe to screen an appropriate library. Alternatively, PCR techniques using oligonucleotide primers that are designed based on known genomic DNA, cDNA and protein sequences can be
25 used to amplify and identify genomic and cDNA sequences.

In another aspect, the present invention provides isolated polypeptides encoded by the above polynucleotides. As used herein, the term "polypeptide" encompasses amino acid chains of any length, including full-length proteins, wherein the amino acid residues are linked by covalent peptide bonds. The term "polypeptide encoded by a
30 polynucleotide" as used herein, includes polypeptides encoded by a polynucleotide that comprises a partial isolated polynucleotide sequence provided herein. In specific embodiments, the inventive polypeptides comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 13-24 and 26, as well as variants of such sequences.

As noted above, polypeptides of the present invention may be produced recombinantly by inserting a polynucleotide sequence of the present invention encoding the polypeptide into an expression vector and expressing the polypeptide in an appropriate host. Any of a variety of expression vectors known to those of ordinary skill in the art may be employed. Expression may be achieved in any appropriate host cell that has been transformed or transfected with an expression vector containing a polynucleotide molecule that encodes a recombinant polypeptide. Suitable host cells include prokaryotes, yeast, and higher eukaryotic cells. Preferably, the host cells employed are plant, *Escherichia coli*, insect, yeast, or a mammalian cell line such as COS or CHO. The polynucleotide sequences expressed in this manner may encode naturally occurring polypeptides, portions of naturally occurring polypeptides, or other variants thereof. The expressed polypeptides may be used in various assays known in the art to determine their biological activity. Such polypeptides may also be used to raise antibodies, to isolate corresponding interacting proteins or other compounds, and to quantitatively determine levels of interacting proteins or other compounds.

In a related aspect, polypeptides are provided that comprise at least a functional portion of a polypeptide having an amino acid sequence selected from the group consisting of sequences provided in SEQ ID NO: 13-24 and 26, and variants thereof. As used herein, the "functional portion" of a polypeptide is that portion which contains an active site essential for affecting the function of the polypeptide, for example, that portion of the molecule that is capable of binding ice crystals. The active site may be made up of separate portions present on one or more polypeptide chains and will generally exhibit high binding affinity. Functional portions of a polypeptide may be identified by first preparing fragments of the polypeptide by either chemical or enzymatic digestion of the polypeptide, or by mutation analysis of the polynucleotide that encodes the polypeptide and subsequent expression of the resulting mutant polypeptides. The polypeptide fragments or mutant polypeptides are then tested to determine which portions retain biological activity, using methods well known to those of skill in the art, including the representative assays described below.

Portions and other variants of the inventive polypeptides may be generated by synthetic or recombinant means. Synthetic polypeptides having fewer than about 100 amino acids, and generally fewer than about 50 amino acids, may be generated using techniques well known to those of ordinary skill in the art. For example, such polypeptides may be synthesized using any of the commercially available solid-phase

techniques, such as the Merrifield solid-phase synthesis method, where amino acids are sequentially added to a growing amino acid chain. See Merrifield, *J. Am. Chem. Soc.* 85: 2149-2146, 1963. Equipment for automated synthesis of polypeptides is commercially available from suppliers such as Perkin Elmer/Applied Biosystems, Inc. 5 (Foster City, California), and may be operated according to the manufacturer's instructions. Variants of a native polypeptide may be prepared using standard mutagenesis techniques, such as oligonucleotide-directed site-specific mutagenesis (Kunkel, *Proc. Natl. Acad. Sci. USA* 82: 488-492, 1985). Sections of DNA sequences may also be removed using standard techniques to permit preparation of truncated 10 polypeptides.

As used herein, the term "variant" comprehends nucleotide or amino acid sequences different from the specifically identified sequences, wherein one or more nucleotides or amino acid residues is deleted, substituted, or added. Variants may be naturally occurring allelic variants, or non-naturally occurring variants. Variant 15 sequences (polynucleotide or polypeptide) preferably exhibit at least 75%, more preferably at least 80%, more preferably at least 90%, more preferably yet at least 95%, and most preferably, at least 98% identity to a sequence of the present invention. The percentage identity is determined by aligning the two sequences to be compared as described below, determining the number of identical residues in the aligned portion, 20 dividing that number by the total number of residues in the inventive (queried) sequence, and multiplying the result by 100.

Polynucleotides and polypeptides having a specified percentage identity to a polynucleotide or polypeptide identified in one of SEQ ID NO: 1-26 thus share a high degree of similarity in their primary structure. In addition to a specified percentage 25 identity to a polynucleotide of the present invention, variant polynucleotides and polypeptides preferably have additional structural and/or functional features in common with a polynucleotide of the present invention. Polynucleotides having a specified degree of identity to, or capable of hybridizing to, a polynucleotide of the present invention preferably additionally have at least one of the following features: (1) they 30 contain an open reading frame, or partial open reading frame, encoding a polypeptide, or a functional portion of a polypeptide, having substantially the same functional properties as the polypeptide, or functional portion thereof, encoded by a polynucleotide in a recited SEQ ID NO.; or (2) they contain identifiable domains in common.

Polynucleotide or polypeptide sequences may be aligned, and percentages of identical nucleotides or amino acids in a specified region may be determined against another polynucleotide or polypeptide, using computer algorithms that are publicly available. The BLASTN and FASTA algorithms, set to the default parameters
 5 described in the documentation and distributed with the algorithm, may be used for aligning and identifying the similarity of polynucleotide sequences. The alignment and similarity of polypeptide sequences may be examined using the BLASTP algorithm. BLASTX and FASTX algorithms compare nucleotide query sequences translated in all reading frames against polypeptide sequences. The FASTA and FASTX algorithms are
 10 described in Pearson and Lipman, *Proc. Natl. Acad. Sci. USA* 85:2444-2448, 1988; and in Pearson, *Methods in Enzymol.* 183:63-98, 1990. The FASTA software package is available from the University of Virginia by contacting the Assistant Provost for Research, University of Virginia, PO Box 9025, Charlottesville, VA 22906-9025. The BLASTN software is available from the National Center for Biotechnology Information
 15 (NCBI), National Library of Medicine, Building 38A, Room 8N805, Bethesda, MD 20894. The BLASTN algorithm Version 2.0.11 [Jan-20-2000] set to the default parameters described in the documentation and distributed with the algorithm, is preferred for use in the determination of polynucleotide variants according to the present invention. The use of the BLAST family of algorithms, including BLASTN,
 20 BLASTP and BLASTX, is described in the publication of Altschul *et al.*, "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs," *Nucleic Acids Res.* 25:3389-3402, 1997.

The following running parameters are preferred for determination of alignments and similarities using BLASTN that contribute to the E values and percentage identity
 25 for polynucleotides: Unix running command with the following default parameters: blastall -p blastn -d embldb -e 10 -G 0 -E 0 -FF -r 1 -v 30 -b 30 -i queryseq -o results; and parameters are: -p Program Name [String]; -d Database [String]; -e Expectation value (E) [Real]; -G Cost to open a gap (zero invokes default behavior) [Integer]; -E Cost to extend a gap (zero invokes default behavior) [Integer]; -FF low complexity
 30 filter; -r Reward for a nucleotide match (BLASTN only) [Integer]; -v Number of one-line descriptions (V) [Integer]; -b Number of alignments to show (B) [Integer]; -i Query File [File In]; -o BLAST report Output File [File Out] Optional.

The following running parameters are preferred for determination of alignments and similarities using BLASTP that contribute to the E values and percentage identity

of polypeptide sequences: `blastall -p blastp -d swissprotrembledb -e 10 -G 0 -E 0 -FF -v 30 -b 30 -i queryseq -o results`; the parameters are: `-p` Program Name [String]; `-d` Database [String]; `-e` Expectation value (E) [Real]; `-G` Cost to open a gap (zero invokes default behavior) [Integer]; `-E` Cost to extend a gap (zero invokes default behavior) [Integer]; `-FF` low complexity filter; `-v` Number of one-line descriptions (v) [Integer]; `-b` Number of alignments to show (b) [Integer]; `-I` Query File [File In]; `-o` BLAST report Output File [File Out] Optional.

The "hits" to one or more database sequences by a queried sequence produced by BLASTN, BLASTP, FASTA, or a similar algorithm, align and identify similar portions of sequences. The hits are arranged in order of the degree of similarity and the length of sequence overlap. Hits to a database sequence generally represent an overlap over only a fraction of the sequence length of the queried sequence.

As noted above, the percentage identity of a polynucleotide or polypeptide sequence is determined by aligning polynucleotide and polypeptide sequences using appropriate algorithms, such as BLASTN or BLASTP, respectively, set to default parameters; identifying the number of identical nucleic or amino acids over the aligned portions; dividing the number of identical nucleic or amino acids by the total number of nucleic or amino acids of the polynucleotide or polypeptide of the present invention; and then multiplying by 100 to determine the percentage identity. By way of example, a queried polynucleotide having 220 nucleic acids has a hit to a polynucleotide sequence in the EMBL database having 520 nucleic acids over a stretch of 23 nucleotides in the alignment produced by the BLASTN algorithm using the default parameters. The 23-nucleotide hit includes 21 identical nucleotides, one gap and one different nucleotide. The percentage identity of the queried polynucleotide to the hit in the EMBL database is thus $21/220$ times 100, or 9.5%. The percentage identity of polypeptide sequences may be determined in a similar fashion.

The BLASTN and BLASTX algorithms also produce "Expect" values for polynucleotide and polypeptide alignments. The Expect value (E) indicates the number of hits one can "expect" to see over a certain number of contiguous sequences by chance when searching a database of a certain size. The Expect value is used as a significance threshold for determining whether the hit to a database indicates true similarity. For example, an E value of 0.1 assigned to a polynucleotide hit is interpreted as meaning that in a database of the size of the EMBL database, one might expect to see 0.1 matches over the aligned portion of the sequence with a similar score simply by

chance. By this criterion, the aligned and matched portions of the sequences then have a probability of 90% of being related. For sequences having an E value of 0.01 or less over aligned and matched portions, the probability of finding a match by chance in the EMBL database is 1% or less using the BLASTN algorithm. E values for polypeptide
5 sequences may be determined in a similar fashion using various polypeptide databases, such as the SwissProt database.

According to one embodiment, "variant" polynucleotides and polypeptides, with reference to each of the polynucleotides and polypeptides of the present invention, preferably comprise sequences having the same number or fewer nucleotides or amino
10 acids than each of the polynucleotides or polypeptides of the present invention and producing an E value of 0.01 or less when compared to the polynucleotide or polypeptide of the present invention. That is, a variant polynucleotide or polypeptide is any sequence that has at least a 99% probability of being related to the polynucleotide or polypeptide of the present invention, measured as having an E value of 0.01 or less
15 using the BLASTN or BLASTX algorithms set at the default parameters. According to a preferred embodiment, a variant polynucleotide is a sequence having the same number or fewer nucleic acids than a polynucleotide of the present invention that has at least a 99% probability of being related to the polynucleotide of the present invention, measured as having an E value of 0.01 or less using the BLASTN algorithm set at the
20 default parameters. Similarly, according to a preferred embodiment, a variant polypeptide is a sequence having the same number or fewer amino acids than a polypeptide of the present invention that has at least a 99% probability of being related as the polypeptide of the present invention, measured as having an E value of 0.01 or less using the BLASTP algorithm set at the default parameters.

25 In an alternative embodiment, variant polynucleotides are sequences that hybridize to a polynucleotide of the present invention under stringent conditions. Stringent hybridization conditions for determining complementarity include salt conditions of less than about 1 M, more usually less than about 500 mM, and preferably less than about 200 mM. Hybridization temperatures can be as low as 5°C, but are
30 generally greater than about 22°C, more preferably greater than about 30°C, and most preferably greater than about 37°C. Longer DNA fragments may require higher hybridization temperatures for specific hybridization. Since the stringency of hybridization may be affected by other factors such as probe composition, presence of organic solvents, and extent of base mismatching, the combination of parameters is

more important than the absolute measure of any one alone. An example of "stringent conditions" is prewashing in a solution of 6X SSC, 0.2% SDS; hybridizing at 65°C, 6X SSC, 0.2% SDS overnight; followed by two washes of 30 minutes each in 1X SSC, 0.1% SDS at 65°C and two washes of 30 minutes each in 0.2X SSC, 0.1% SDS at 65°C.

5 The present invention also encompasses polynucleotides that differ from the disclosed sequences but that, as a consequence of the discrepancy of the genetic code, encode a polypeptide having similar functional activity to a polypeptide encoded by a polynucleotide of the present invention. Thus, polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NO: 1-12 and 25, or
10 complements, reverse sequences, or reverse complements of those sequences, as a result of conservative substitutions are contemplated by and encompassed within the present invention. Additionally, polynucleotides comprising sequences that differ from the polynucleotide sequences recited in SEQ ID NO: 1-12 and 25, or complements, reverse complements or reverse sequences thereof, as a result of deletions and/or insertions
15 totaling less than 10% of the total sequence length are also contemplated by and encompassed within the present invention. Similarly, polypeptides comprising sequences that differ from the polypeptide sequences recited in SEQ ID NO: 13-24 and 26 as a result of amino acid substitutions, insertions, and/or deletions totaling less than 10% of the total sequence length are contemplated by and encompassed within the
20 present invention, provided the variant polypeptide has activity in a lignin, fructan or tannin biosynthetic pathway.

In another aspect, the present invention provides genetic constructs comprising, in the 5'-3' direction, a gene promoter sequence; an open reading frame coding for at least a functional portion of a polypeptide of the present invention; and a gene
25 termination sequence. The open reading frame may be orientated in either a sense or anti-sense direction. For applications where amplification of cold tolerance is desired, the open reading frame may be inserted in the construct in a sense orientation, such that transformation of a target organism with the construct will lead to an increase in the number of copies of the gene and therefore an increase in the amount of polypeptide.
30 When down-regulation of cold tolerance is desired, the open reading frame may be inserted in the construct in an anti-sense orientation, such that the RNA produced by transcription of the polynucleotide is complementary to the endogenous mRNA sequence. This, in turn, will result in a decrease in the number of copies of the gene and

therefore a decrease in the amount of polypeptide. Alternatively, regulation may be achieved by inserting appropriate sequences or subsequences (e.g., DNA or RNA) in ribozyme constructs.

Genetic constructs comprising a non-coding region of a gene coding for a polypeptide of the present invention, or a nucleotide sequence complementary to a non-coding region, together with a gene promoter sequence and a gene termination sequence, are also provided. As used herein the term "non-coding region" includes both transcribed sequences that are not translated, and non-transcribed sequences within about 2000 base pairs 5' or 3' of the translated sequences or open reading frames. Examples of non-coding regions that may be usefully employed in the inventive constructs include introns and 5'-non-coding leader sequences. Transformation of a target organism with such a genetic construct may lead to a reduction in the cold tolerance the plant by the process of cosuppression, in a manner similar to that discussed, for example, by Napoli *et al.*, *Plant Cell* 2:279-290, 1990; and de Carvalho Niebel *et al.*, *Plant Cell* 7:347-358, 1995.

The genetic constructs of the present invention further comprise a gene promoter sequence and a gene termination sequence, operably linked to the polynucleotide to be transcribed, which control expression of the gene. The gene promoter sequence is generally positioned at the 5' end of the polynucleotide to be transcribed, and is employed to initiate transcription of the polynucleotide. Gene promoter sequences are generally found in the 5' non-coding region of a gene but they may exist in introns (Luehrsen, *Mol. Gen. Genet.* 225:81-93, 1991). When the construct includes an open reading frame in a sense orientation, the gene promoter sequence also initiates translation of the open reading frame. For genetic constructs comprising either an open reading frame in an anti-sense orientation or a non-coding region, the gene promoter sequence consists only of a transcription initiation site having a RNA polymerase binding site.

A variety of gene promoter sequences that may be usefully employed in the genetic constructs of the present invention are well known in the art. The promoter gene sequence, and also the gene termination sequence, may be endogenous to the target host or may be exogenous, provided the promoter is functional in the target host. For example, the promoter and termination sequences may be from other plant species, plant viruses, bacterial or archaeal plasmids and the like. Preferably, gene promoter and termination sequences are from the inventive sequences themselves.

Factors influencing the choice of promoter include the desired tissue specificity of the construct, and the timing of transcription and translation. For example, constitutive promoters, such as the 35S Cauliflower Mosaic Virus (CaMV 35S) promoter, will affect the activity of the enzyme in all parts of the plant. Use of a tissue
5 specific promoter will result in production of the desired sense or anti-sense RNA only in the tissue of interest. With genetic constructs employing inducible gene promoter sequences, the rate of RNA polymerase binding and initiation can be modulated by external physical or chemical stimuli, such as light, heat, anaerobic stress, alteration in nutrient conditions and the like. Temporally regulated promoters can be employed to
10 effect modulation of the rate of RNA polymerase binding and initiation at a specific time during development of a transformed cell. Preferably, the original promoters from the gene in question, or promoters from a specific tissue-targeted gene in the organism to be transformed, such as *Lolium* or *Festuca*, are used. Promoters different from the original gene may also be usefully employed in the inventive genetic constructs in order
15 to prevent feedback inhibition. Other examples of gene promoters which may be usefully employed in the present invention include, mannopine synthase (mas), octopine synthase (ocs) and those reviewed by Chua *et al.*, *Science* 244:174-181, 1989.

The gene termination sequence, which is located 3' to the polynucleotide to be transcribed, may come from the same gene as the gene promoter sequence or may be
20 from a different gene. Many gene termination sequences known in the art may be usefully employed in the present invention, such as the 3' end of the *Agrobacterium tumefaciens* nopaline synthase gene. However, preferred gene terminator sequences are those from the original gene or from the target species to be transformed.

The genetic constructs of the present invention may also contain a selection
25 marker that is effective in cells, such as plant cells, to allow for the detection of transformed cells containing the inventive construct. Such markers, which are well known in the art, typically confer resistance to one or more toxins. One example of such a marker is the NPTII gene whose expression results in resistance to kanamycin or hygromycin, antibiotics which are usually toxic to plant cells at a moderate
30 concentration (Rogers *et al.*, in Weissbach A and H, eds., *Methods for Plant Molecular Biology*, Academic Press Inc.: San Diego, CA, 1988). Alternatively, the presence of the desired construct in transformed cells can be determined by means of other techniques well known in the art, such as Southern and Western blots.

Techniques for operatively linking the components of the inventive genetic constructs are well known in the art and include the use of synthetic linkers containing one or more restriction endonuclease sites as described, for example, by Sambrook *et al.*, (*Molecular cloning: a laboratory manual*, CSHL Press: Cold Spring Harbor, NY, 5 1989). The genetic construct of the present invention may be linked to a vector having at least one replication system, for example, *Escherichia coli*, whereby after each manipulation, the resulting construct can be cloned and sequenced and the correctness of the manipulation determined.

The genetic constructs of the present invention may be used to transform a 10 variety of organisms including mammals, insects, fungi, archaea and bacteria, in addition to plants, both monocotyledonous (*e.g.*, grasses, maize/corn, grains, oats, rice, sorghum, millet, rye, sugar cane, wheat and barley), dicotyledonous (*e.g.*, *Arabidopsis*, tobacco, legumes, alfalfa, oaks, eucalyptus, maple), and gymnosperms. In a preferred embodiment, the inventive genetic constructs are employed to transform grasses. 15 Preferably the target plant is selected from the group consisting of *Lolium* and *Festuca* species, most preferably from the group consisting of *Lolium perenne* and *Festuca arundinacea*. Other species of ryegrass and fescue that may be usefully transformed with the inventive genetic constructs, include, but are not limited to *Lolium multiflorum* (Italian ryegrass), *Lolium hybridum* (hybrid ryegrass), *Lolium rigidum* (Wimmera grass), 20 *Lolium temulentum* (darnel), *Festuca rubra* (red fescue) and *Festuca pratensis* (meadow fescue). Other plants that may be usefully transformed with the inventive genetic constructs include cold intolerant trees, such as eucalyptus, and high value crops, such as cherries, stone fruit (for example, peaches), apples, pears, walnuts, almonds, peanuts, wine grapes, potatoes and tomatoes. As discussed above, 25 transformation of a organism with a genetic construct of the present invention will produce a modified cold tolerance in the plant.

The production of RNA in target cells may be controlled by choice of the promoter sequence, or by selecting the number of functional copies or the site of integration of the polynucleotides incorporated into the genome of the target organism. 30 A target organism may be transformed with more than one construct of the present invention, thereby affecting AFP activity in more than one tissue or affecting AFP activity at more than one expression time. Similarly, a construct may be assembled containing more than one open reading frame coding for an AFP encoded by a polynucleotide of the present invention or more than one non-coding region of a gene

coding for such an AFP. A cooperative effect has been observed in AFPs from winter rye (Wai-Ching Hon *et al.*, *Plant Physiol.* 104:971-980, 1994) and from fish (Mulvihill *et al.*, *J. Biol. Chem.* 255:659-662, 1979; Osuga *et al.*, *J. Biol. Chem.* 235:6669-6672, 1978), indicating that the use of more than AFP of the present invention may be
5 beneficial. The polynucleotides of the present invention may also be employed in combination with other known sequences.

Techniques for stably incorporating genetic constructs into the genome of target organisms are well known in the art. Techniques for transforming plants include *Agrobacterium tumefaciens* mediated introduction, electroporation, protoplast fusion,
10 injection into reproductive organs, injection into immature embryos, high velocity projectile introduction and the like. The choice of technique will depend upon the target plant to be transformed. For example, dicotyledonous plants and certain monocots and gymnosperms may be transformed by *Agrobacterium* Ti plasmid technology, as described, for example by Bevan, *Nucleic Acid Res.* 12:8711-8721, 1984. Targets for
15 the introduction of the DNA constructs of the present invention include tissues, such as leaf tissue, disseminated cells, protoplasts, seeds, embryos, meristematic regions; cotyledons, hypocotyls, and the like. Transformation techniques which may be usefully employed in the inventive methods include those taught by Ellis *et al.*, *Plant Cell Reports*, 8:16-20, 1989, Wilson *et al.*, *Plant Cell Reports* 7:704-707, 1989, Tautorius *et al.*, *Theor. Appl. Genet.* 78:531-536, 1989 and Ishida *et al.*, *Nat. Biotechnol.* 14:745-
20 750, 1996.

Once the cells are transformed, cells having the inventive genetic construct incorporated in their genome may be selected by means of a marker, such as the kanamycin resistance marker discussed above. Transgenic cells may then be cultured in
25 an appropriate medium to regenerate whole organisms, such as plants, using techniques well known in the art. In the case of protoplasts, the cell wall is allowed to reform under appropriate osmotic conditions. In the case of seeds or embryos, an appropriate germination or callus initiation medium is employed. For explants, an appropriate regeneration medium is used. Regeneration of plants is well established for many
30 species. The resulting transformed plants may be reproduced sexually or asexually, using methods well known in the art, to give successive generations of transgenic plants.

Polypeptides of the present invention may be transiently expressed in target plants by means of viral vectors as described, for example by Fischer *et al.*, *Biotechnol.*

Appl. Biochem. 30:113-116, 1999. In such methods, a polynucleotide encoding the polypeptide of interest is cloned into the genome of a viral plant pathogen. The resulting infectious recombinant viral transcripts are used to infect plants and produce the polypeptide of interest. Techniques for employing recombinant plant viral vectors to transiently express proteins in plants are well known in the art and include those disclosed in US Patent 6,369,296, the disclosure of which is hereby incorporated by reference. Introduction of the inventive AFPs using such viral vectors is particularly useful for frost protection of fruit trees, where transient expression of AFPs in frost sensitive parts of the trees, such as young floral/fruitlet and leaf buds would be very valuable.

Polynucleotides of the present invention may also be used to specifically suppress gene expression by methods that operate post-transcriptionally to block the synthesis of products of targeted genes, such as RNA interference (RNAi), and quelling. For a review of techniques of gene suppression see *Science*, 288:1370-1372, 2000. Exemplary gene silencing methods are also provided in WO 99/49029 and WO 99/53050. Posttranscriptional gene silencing is brought about by a sequence-specific RNA degradation process which results in the rapid degradation of transcripts of sequence-related genes. Studies have provided evidence that double-stranded RNA may act as a mediator of sequence-specific gene silencing (see, e.g., review by Montgomery and Fire, *Trends in Genetics*, 14: 255-258, 1998). Gene constructs that produce transcripts with self-complementary regions are particularly efficient at gene silencing. A unique feature of this posttranscriptional gene silencing pathway is that silencing is not limited to the cells where it is initiated. The gene-silencing effects may be disseminated to other parts of an organism and even transmitted through the germ line to several generations.

The polynucleotides of the present invention may be employed to generate gene silencing constructs and or gene-specific self-complementary RNA sequences that can be delivered by conventional art-known methods to tissues, such as plant tissues. Within genetic constructs, sense and antisense sequences can be placed in regions flanking an intron sequence in proper splicing orientation with donor and acceptor splicing sites, such that intron sequences are removed during processing of the transcript and sense and antisense sequences, as well as splice junction sequences, bind together to form double-stranded RNA. Alternatively, spacer sequences of various lengths may be employed to separate self-complementary regions of sequence in the

construct. During processing of the gene construct transcript, intron sequences are spliced-out, allowing sense and anti-sense sequences, as well as splice junction sequences, to bind forming double-stranded RNA. Select ribonucleases bind to and cleave the double-stranded RNA, thereby initiating the cascade of events leading to
5 degradation of specific mRNA gene sequences, and silencing specific genes. Alternatively, rather than using a gene construct to express the self-complementary RNA sequences, the gene-specific double-stranded RNA segments are delivered to one or more targeted areas to be internalized into the cell cytoplasm to exert a gene silencing effect. Gene silencing RNA sequences comprising the polynucleotides of the
10 present invention are useful for creating genetically modified plants with desired phenotypes as well as for characterizing genes (e.g., in high-throughput screening of sequences), and studying their functions in intact organisms.

In another embodiment, one or more of the inventive polypeptides may be employed in foliar applicants to protect target plants from damage due to low
15 temperatures and, in particular, from frost and/or freezing. Techniques for preparing and applying foliar applicants are well known and include those described in U.S. Patents 6,180,562 and 6,588,142. Preferably, foliar applicants comprising the inventive polypeptides are applied before early spring and early fall/autumn frosts in order to minimize damage to cold intolerant crops.

20 For use as foliar applicants, the inventive polypeptides may be formulated with known agricultural carriers, such as, but not limited to: water; alcohols; ketones; ethers; aliphatic hydrocarbons; aromatic hydrocarbons; sulfur-containing compounds; and powders of plant or animal origin, such as starch, activated carbon, calcium carbonate, talc, soybean flour, wheat flour. Such formulations may also, or alternatively, contain
25 an adjuvant, such as an extender, penetrant or surfactant. Extenders are adjuvants that can extend the useful life of a spray chemical, by increasing the chemical's adhesion to the leaf, by reducing any factor that can diminish chemical effectiveness, or by enhancing chemical weatherability. Some extenders have the ability to intercept ultraviolet light. Penetrants are adjuvants that help chemicals penetrate plants.
30 Surfactants are adjuvants that reduce the surface tensions of solutions, helping them spread and cover surfaces more effectively. Surfactants are probably the best-known class of adjuvants. Most adjuvants are a double-ended molecule, with one end being water soluble and one end being oil soluble. These molecules can therefore line-up between water-like compounds and oil-like compounds and make them more

compatible. Surfactants can be uncharged (non-ionic), positively charged (cationic), or negatively charged (anionic). Specific examples of these compounds include Agral™, Ethokem™, Silwet-77™, Sylgard 309™, Actipron™, Codacide™, Actirob™ and the Brij™ series of compounds.

5 The resulting formulations may be in any form known in the art, such as liquids, dusts, granules, powders, emulsifiable concentrations, aerosols or pastes, and may be applied by conventional methods, such as spraying, jetting, misting, atomizing, soil application and surface application. The foliar applicants may also include additional components such as emulsifiers, suspending agents, dispersants, wetting agents,
10 thickeners and/or stabilizers, and may be used in combination with other active compounds, such as insecticides, herbicides and fungicides. The amount of polypeptide present within the foliar applicant will vary depending upon the formulation, manner and timing of application, condition of plants, and risk of frost or freeze damage. Preferably the polypeptide is present in a concentration of between 0.1 and 500,000
15 ppm, preferably between 1 and 100,000 ppm.

 In another aspect, the present invention provides methods for using one or more of the inventive polypeptides or polynucleotides to treat disorders in a patient, preferably a mammal, more preferably a human. Disorders that may be treated using the inventive polypeptides and/or polynucleotides include those characterized by the
20 unwanted presence of biocrystals, such as gout and kidney stones.

 In this aspect, the polypeptide or polynucleotide is generally present within a composition, such as a pharmaceutical or immunogenic composition. Pharmaceutical compositions may comprise one or more polypeptides, each of which may contain one or more of the above sequences (or variants thereof), and a physiologically acceptable
25 carrier. Immunogenic compositions may comprise one or more of the above polypeptides and an immunostimulant, such as an adjuvant or a liposome, into which the polypeptide is incorporated.

 Alternatively, a composition of the present invention may contain DNA encoding one or more polypeptides described herein, such that the polypeptide is
30 generated *in situ*. In such compositions, the DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, and bacterial and viral expression systems. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminator signal). Bacterial delivery

systems involve the administration of a bacterium (such as *Bacillus Calmette-Guerin*) that expresses an immunogenic portion of the polypeptide on its cell surface. In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other poxvirus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic, or defective, replication competent virus. Techniques for incorporating DNA into such expression systems are well known in the art. The DNA may also be "naked," as described, for example, in Ulmer *et al.*, *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells.

While any suitable carrier known to those of ordinary skill in the art may be employed in the pharmaceutical compositions of this invention, the type of carrier will vary depending on the mode of administration. For parenteral administration, such as subcutaneous injection, the carrier preferably comprises water, saline, alcohol, a lipid, a wax or a buffer. For oral administration, any of the above carriers or a solid carrier, such as mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, sucrose, and magnesium carbonate, may be employed. Biodegradable microspheres (e.g., polylactic galactide) may also be employed as carriers for the pharmaceutical compositions of this invention. Suitable biodegradable microspheres are disclosed, for example, in U.S. Patent Nos. 4,897,268 and 5,075,109.

Any of a variety of adjuvants may be employed in the immunogenic compositions of the present invention to non-specifically enhance an immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a non-specific stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *M. tuberculosis*. Suitable adjuvants are commercially available as, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories, Detroit, MI), and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ). Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A and Quil A.

Routes and frequency of administration of the inventive compositions, as well as dosage, vary from individual to individual. In general, the inventive compositions may be administered by injection (e.g., intradermal, intramuscular, intravenous or subcutaneous), intranasally (e.g., by aspiration) or orally. Preferably, the AFPs of the present invention are injected into the affected area or administered in a topical

application which is absorbed by the skin. In general, the amount of polypeptide present in a dose (or produced *in situ* by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg per kg of host, and preferably from about 100 pg to about 1 µg per kg of host. Suitable dose sizes will vary with the size of the patient, but will typically range from about 0.1 ml to about 2 ml.

Solutions comprising the inventive polypeptides may also be employed to improve the effectiveness of cryosurgery in, for example, the removal of unwanted tissue, such as tumor tissue. In such methods, the unwanted tissue is perfused with a solution preferably comprising between 1mg/ml to about 30 mg/ml of the polypeptide. This can be accomplished, for example, by injection into the tissue, ingestion, or perfusion through the vasculature. Once the tissue is perfused with the polypeptide, cryoablation of the tissue is performed using a standard techniques employing, for example, a cryogenic probe. Cryogenic probes are preferably used in combination with real-time imaging techniques, such as ultrasound and magnetic resonance imaging.

The inventive polypeptides and/or polynucleotides may also be employed as hydrate inhibitors in, for example, natural gas transmission lines. Gas hydrates form when water molecules crystallize around natural gas guest molecules. This co-crystallization process, which has been recognized for several years, is well characterized and occurs with the right combination of temperature and pressure. Gas hydrates may form in any place where water coexists with natural gas at temperatures as high as 80° F. Long gas transmission lines are particularly vulnerable to hydrate blockage during extended cold weather periods. Sub-sea pipelines may have hydrate problems continually due to the cooling effect of seawater at depth. While there are a few known methods of preventing hydrate formation, thermodynamic solutions such as removing the water, heating the system and lowering the pressure, are often not practical. Another thermodynamic method, the addition of sufficient amounts of ethylene glycol or methanol to decrease hydrate stability, effectively lowers the temperature of hydrate formation. This method requires relatively large amounts of ethylene glycol or methanol, which are inconvenient to use and hazardous due to both chemical toxicity and flammability. This method of treatment can also be quite expensive. Use of the inventive AFPs would be a safer alternative to the use of ethylene glycol and/or methanol

Another application of the inventive AFPs is in any spraying process which uses a solution (containing water) at freezing temperatures. One or more of the inventive AFPs could be employed as an anti-clogging agent, by reducing the size of ice crystal to provide a reduced frequency of blocking in the spraying nozzles. This effect might also
5 be applied in the sugar industry where a solution of sugar is sprayed to crystallize and dry it. AFPs could be employed to prevent clogging of the nozzles by reducing and controlling crystal size, with at the same time having the added benefit of reducing drying time.

10 The following examples are offered by way of illustration and not by way of limitation.

Example 1ISOLATION OF cDNA SEQUENCES FROM *L. PERENNE* AND
F. ARUNDINACEA cDNA LIBRARIES

5 *L. perenne* and *F. arundinacea* cDNA expression libraries were constructed and screened as follows. Tissue was collected from *L. perenne* and *F. arundinacea* during winter and spring, and snap-frozen in liquid nitrogen. The tissues collected include those obtained from leaf blades, leaf base, pseudostem, roots and stem. Total RNA was isolated from each tissue type using TRIzol Reagent (BRL Life Technologies,
10 Gaithersburg, MD). mRNA from each tissue type was obtained using a Poly(A) Quik mRNA isolation kit (Stratagene, La Jolla, CA), according to the manufacturer's specifications. cDNA expression libraries were constructed from the purified mRNA by reverse transcriptase synthesis followed by insertion of the resulting cDNA in Lambda ZAP using a ZAP Express cDNA Synthesis Kit (Stratagene), according to the
15 manufacturer's protocol. The resulting cDNA clones were packaged using a Gigapack II Packaging Extract (Stratagene) employing 1 µl of sample DNA from the 5 µl ligation mix. Mass excision of the libraries was done using XL1-Blue MRF' cells and XL0LR cells (Stratagene) with ExAssist helper phage (Stratagene). The excised phagemids were diluted with NZY broth (Gibco BRL, Gaithersburg, MD) and plated out onto
20 LB-kanamycin agar plates containing 5-bromo-4-chloro-3-indolyl-beta-D-galactosidase (X-gal) and isopropylthio-beta-galactoside (IPTG).

Of the colonies plated and picked for DNA preparations, the large majority contained an insert suitable for sequencing. Positive colonies were cultured in NZY broth with kanamycin and DNA was purified following standard protocols. Agarose
25 gel at 1% was used to screen sequencing templates for chromosomal contamination. Dye terminator sequences were prepared using a Biomek 2000 robot (Beckman Coulter Inc., Fullerton, CA) for liquid handling and DNA amplification using a 9700 PCR machine (Perkin Elmer/Applied Biosystems, Foster City, CA) according to the manufacturer's protocol.

30 The DNA sequences for positive clones were obtained using a Perkin Elmer/Applied Biosystems Division Prism 377 sequencer. cDNA clones were sequenced from the 5' end. The polynucleotide sequences identified as SEQ ID NOS: 3 and 10 were identified from *L. perenne* leaf blade cDNA expression libraries; the polynucleotide sequences identified as SEQ ID NOS: 8 and 12 were identified from *L.*

perenne leaf and pseudostem cDNA expression libraries; the polynucleotide sequence identified as SEQ ID NO: 1 was identified from *L. perenne* pseudostem cDNA expression libraries; the polynucleotide sequences identified as SEQ ID NOS: 5, 6 and 25 were identified from a *L. perenne* root cDNA expression library; the polynucleotide sequences identified as SEQ ID NOS: 4, 7, 9 and 11 were identified from *F. arundinacea* leaf blade cDNA expression libraries; and the polynucleotide sequence identified as SEQ ID NO: 2 was identified from *F. arundinacea* basal stem cDNA expression libraries. All of the sequences of SEQ ID NO: 1-12 are believed to be full-length. The amino acid sequences corresponding to the cDNA sequences of SEQ ID NO: 1-12 and 25 are provided in SEQ ID NO: 13-24 and 26, respectively.

BLASTN Polynucleotide Analysis

The isolated cDNA sequences were compared to sequences in the EMBL DNA database using the computer algorithm BLASTN. Comparisons of DNA sequences provided in SEQ ID NOS: 1-12 to sequences in the EMBL DNA database were made as of August 23, 2002, using BLASTN algorithm Version 2.0.11 [Jan-20-2000] and the following Unix running command: `blastall -p blastn -d embldb -e 10 -G0 -E0 -FF -r 1 -v 30 -b 30 -i queryseq -o`. Comparisons of the DNA sequence provided in SEQ ID NO: 25 to sequences in the EMBL DNA database were made as of August 15, 2003, using BLASTN algorithm Version 2.0.11 [Jan-20-2000] and the same Unix running command.

The sequences of SEQ ID NOS: 1-12 and 25 were determined to have less than 50% identity to sequences in the EMBL database using the computer algorithm BLASTN, as described above.

BLASTP Polypeptide Analysis

Comparisons of protein sequences provided in SEQ ID NOS: 13-24, to sequences in the SwissProt- TrEMBLE protein database were made as of August 23, 2002 using BLASTP algorithm Version 2.0.11 [Jan-20-2000], and the following Unix running command: `blastall -p blastp -d swissprottrembledb -e 10 -G0 -E0 -FF -v 30 -b 30 -i queryseq -o`. Comparison of the protein sequence provided in SEQ ID NO: 26 to sequences in the SwissProt-TrEMBLE protein database were made as of August 15, 2003 using BLASTP algorithm Version 2.0.11 [Jan-20-2000] and the same Unix running command.

The sequences of SEQ ID NOS: 13-24 and 26 were determined to have less than 50% identity to sequences in the SwissProt-TrEMBLE database determined as described above using the computer algorithm BLASTP.

5 BLASTX Polynucleotide Analysis

Comparisons of DNA sequences provided in SEQ ID NOS: 1-12, to sequences in the SwissProt-TrEMBLE protein database (using BLASTX) were made as of August 23, 2002 using BLAST algorithm Version 2.0.11 [Jan-20-2000], and the following Unix running command: blastall -p blastx -d swissprottrrembledb -e 10 -G0 -E0 -FF
 10 -v 30 -b 30 -i queryseq -o. Comparison of the DNA sequence provided in SEQ ID NO: 25 to sequences in the SwissProt-TrEMBLE protein database (using BLASTX) were made as of August 15, 2003 using BLAST algorithm Version 2.0.11 [Jan-20-2000] and the same Unix running command.

The sequences of SEQ ID NOS: 1-12 and 25 were determined to have less than
 15 50% identity to sequences in the SwissProt-TrEMBLE database, determined as described above using the computer algorithm BLASTX.

The location of open reading frames (ORFs), by nucleotide position, contained within the sequences of SEQ ID NO: 1-12 and 25, and the corresponding amino acid sequences are provided in Table 2 below.

20

TABLE 2

POLYNUCLEOTIDE SEQ ID NO:	ORF	POLYPEPTIDE SEQ ID NO:
1	55-786	13
2	82-813	14
3	35-838	15
4	41-850	16
5	60-905	17
6	77-910	18
7	59-892	19
8	55-897	20
9	53-910	21
10	79-843	22
11	53-841	23
12	72-842	24
25	59-904	26

Example 2USE OF GRASS ANTI-FREEZE PROTEIN GENES TO ALTER ICE CRYSTAL STRUCTURETransformation of *Arabidopsis* plants with grass anti-freeze protein genes

5 Sense constructs containing a polynucleotide including the coding region of AFP genes isolated from *Lolium perenne* or *Festuca arundinacea* (SEQ ID NOS: 1, 3, 5, 8 and 10) were inserted into a binary vector and used to transform *Agrobacterium tumefaciens* LBA4404 using published methods (see, An G, Ebert PR, Mitra A, Ha SB, "Binary Vectors," in Gelvin SB, Schilperoort RA, eds., *Plant Molecular Biology*
10 *Manual*, Kluwer Academic Publishers: Dordrecht, 1988). The presence and integrity of the binary vector in *A. tumefaciens* was verified by the polymerase chain reaction (PCR) using vector primers.

 The *A. tumefaciens* containing the sense gene constructs were used to transform *Arabidopsis*, by floral dipping (Clough and Bent, *Plant J.* 16:735-743, 1998). Several
15 independent transformed plant lines were established for the sense construct for each gene. Transformed plants were allowed to self fertilize and T1 seed collected. A number of T2 plants from each original T1 plant were tested to confirm the presence of the appropriate anti-freeze gene construct by PCR analysis of genomic DNA. The primers listed in SEQ ID NOS: 27 and 28 were used for AFP1 (SEQ ID NO: 1), the
20 primers listed in SEQ ID NOS: 29 and 30 were used for AFP2 (SEQ ID NO: 3), the primers listed in SEQ ID NOS: 31 and 32 were used for AFP4 (SEQ ID NO: 8), and the primers listed in SEQ ID NOS: 33 and 34 were used for AFP5 (SEQ ID NO: 10). No transgene was seen in the empty-vector transformed control plants.

25 Increased freezing tolerance of the AFP-expressing plants

 Plants are tested for increased survival after enduring freezing conditions, in comparison to wild type empty vector control *Arabidopsis*. A plate-based assay is employed, similar to previous assays that tested *Arabidopsis* mutants for changes in freezing tolerance (Chinnusamy *et al.*, *Genes Dev.* 17:1043–1054, 2003). Briefly, 90
30 T2 seedlings of each line, 10 independent transgenic lines per construct, are sown on to MS plus sucrose agar plates. The seed is stratified at 4°C for 2 days before germinating at 22°C for 10 days, followed by a 4 day cold acclimation at 4°C, low light. The seedlings are then subjected to a freezing cycle in a controlled environment unit. Plates are incubated at -1°C for 16 hours and sprinkled with ice chips to attain even freezing.

The temperature is lowered at 1°C per hour to either -10°C or -12°C and the minimum temperature is maintained for 2 hours before placing the plants at 4°C for 12 hours to thaw. The plants are then kept at 22°C and visually scored for survival after 2 days.

5

Example 3

USE OF GRASS ANTI-FREEZE PROTEIN GENES TO CHANGE ICE CRYSTAL SIZE

A number of grass anti-freeze protein genes (SEQ ID NOS: 1, 3, 5, and 11), as well as a truncated gene derived from AFP1 (SEQ ID NO: 1), were expressed in
10 *Escherichia coli* and purified using standard protocols. The grass genes were amplified by PCR using the forward and reverse primers listed in SEQ ID NOS: 35 and 36 for AFP1 (SEQ ID NO: 1), SEQ ID NOS: 39 and 40 for AFP2 (SEQ ID NO: 3), SEQ ID NOS: 41 and 42 for AFP3 (SEQ ID NO: 5), and SEQ ID NOS: 43 and 44 for AFP5 (SEQ ID NO: 11). The truncated AFP1 gene was amplified using the primers given in
15 SEQ ID NOS: 37 and 38. The resulting fragments were cloned into a modified pET16b expression plasmid (six histidines followed by an *EcoRI* site then the *BamHI* site) in frame with the histidine Tag sequence. The resulting plasmids were transformed into *Escherichia coli* BL21 cells using standard protocols and protein expression induced using IPTG. The insoluble recombinant proteins in the form of inclusion bodies were
20 extracted from bacterial cells by multi-phase sonication in a buffer consisting of 2M urea, 20 mM Tris-HCl, 0.5 M NaCl and 2 % Triton X-100 at a pH of 8.0. The resulting proteins were solubilized over the course of one hour in a buffer consisting of 6 M guanidinium hydrochloride, 20 mM Tris-HCl, 0.5 M NaCl, 10 mM imidazole and 1 mM 2-mercaptoethanol at a pH of 8.0. Target proteins were purified by His Tag
25 binding affinity chromatography on Chelating Sepharose Fast Flow columns, previously charged with NiSO₄. A one hour linear gradient of 6 M to 0 M urea, at a flow rate of 0.4 ml/ min was used to refold the target proteins on the affinity matrix. Elution using a buffer containing 20 mM Tris-HCl, 0.5 M NaCl, 0.5 M imidazole and 1 mM 2-mercaptoethanol at a pH of 8.0 followed this. Eluted material was subjected to
30 electrophoresis on a 4-12 % NuPAGE gel and visualised by staining using Coomassie Brilliant Blue. Intensely stained purified bands were identified for protein genes SEQ ID NO: 1, 3, 5 and 11. These were further confirmed by trypsin digestion of soluble protein fractions or protein gel band isolation followed by mass spectrometry.

Digested fragments were compared to the Mass Spectrometry Data Base (MSDB) where proteins encoded by the DNA sequences of SEQ ID NO: 3, 5 and 11 (amino acid sequences provided in SEQ ID NO: 15, 17 and 23, respectively) were positively identified. The protein gene product of SEQ ID NO: 1 (amino acid sequence provided in SEQ ID NO: 13) was identified by comparison to a limited in-house database. Proteins with SEQ ID NO: 15, 17 and 23 were dialyzed against 20 mM Tris-HCl at pH 8.0. In addition, proteins with SEQ ID NO: 13, 15, 17 and 23 were also maintained in their elution state *i.e.* in a buffer containing 20 mM Tris-HCl, 0.5 M NaCl, 0.5 M imidazole and 1 mM 2-mercaptoethanol at a pH of 8.0.

10 The purified protein of SEQ ID NO: 23, encoded by SEQ ID NO: 11, was tested in the "SPLAT" assay (Smallwood *et al.*, *Biochem. J.* 340:385-391, 1999) to investigate its impact on ice restructuring. In the sucrose-sandwich-splat assay, 2 µl of purified protein in 30% (w/w) sucrose was squashed between 13 mm circular cover slips. The 'sandwich' was dropped into a bath of heptane held at -80 °C in a box of solid CO₂ and
15 transferred into a glass viewing chamber containing heptane maintained at -6°C by a circulating cooler (Grant). Ice crystals were viewed using a 20x objective on an Optiphot microscope (Nikon) and images captured at 0 and 30 minutes incubation at -6°C using a video camera into an image analysis system (LUCIA, Nikon). The results showed that antifreeze protein AFP5, corresponding to the product from SEQ ID NO:
20 11, inhibited ice recrystallization at a concentration of 0.9 and 1.8 mg/ml. The effects could clearly be observed at the initiation of the assay *i.e.* time = zero minutes, but were far more pronounced at the thirty-minute interval. At this point the ice crystals formed using the 20 mM Tris-HCl control were many fold larger than the ice crystals formed in the presence of AFP5 at either 0.5 or 1.0 mg/ml. AFP5 also displayed a concentration
25 effect where the ice crystals formed at the higher concentration were smaller than those that propagated at the lower concentration.

As the SPLAT assay is performed in 30% sucrose, these results also showed that AFP5 is able to modify sucrose solutions.

Example 4

USE OF GRASS ANTI-FREEZE PROTEIN GENES TO REDUCE DRYING TIME

Antifreeze proteins AFP2, AFP3 and AFP5 corresponding to the products from
5 SEQ ID NOS: 3, 5 and 11 (amino acid sequences provided in SEQ ID NO: 15, 17 and
23, respectively) were tested for their ability to increase the rate of drying of liquids in a
SpeedVacTM vacuum concentrator set at medium heat. After dialysis against 20 mM
Tris-HCl pH 8.0, the concentration of Tris-HCl was adjusted to 8 mM. AFPs in Tris
buffer were pipetted into 1.5 ml eppendorf tubes such that each tube contained 500 µl of
10 liquid. Antifreeze proteins were in the range of 0.1 µg to 200 µg in 500 µl volumes.
Controls of either 500 µl 8 mM Tris or 500 µl MilliQ water were used. AFP2 and
AFP3, at a concentration of 20 to 100 µg/ml facilitated rapid drying of 500 µl of 8 mM
Tris-HCl in 75 minutes. Controls remained at volumes of 200-300 µl after 4 hours of
vacuum drying. AFP5 at a concentration of between 100 and 400 µg/ml reduced in
15 volume to approximately 20-50 µl after 4 hours. This compared favorably to controls,
which had volumes of 200-300 µl after 4 hours. These results demonstrate that AFPs
used as additives reduced the drying time significantly.

20 SEQ ID NOS: 1-44 are set out in the attached Sequence Listing. The codes for
nucleotide sequences used in the attached Sequence Listing, including the symbol "n,"
conform to WIPO Standard ST.25 (1998), Appendix 2, Table 1.

All references cited herein, including patent references and non-patent
publications, are hereby incorporated by reference in their entireties.

25 While in the foregoing specification this invention has been described in relation
to certain preferred embodiments, and many details have been set forth for purposes of
illustration, it will be apparent to those skilled in the art that the invention is susceptible
to additional embodiments and that certain of the details described herein may be varied
considerably without departing from the basic principles of the invention.

Claims

We claim:

1. An isolated polynucleotide comprising a sequence selected from the group consisting of: SEQ ID NO: 1-12 and 25.
2. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) complements of SEQ ID NO: 1-12 and 25;
 - (b) reverse complements of SEQ ID NO: 1-12 and 25;
 - (c) reverse sequences of SEQ ID NO: 1-12 and 25;
 - (d) sequences that are 100-mers of a sequence of SEQ ID NO: 1-12 and 25;
 - (e) sequences that are 40-mers of a sequence of SEQ ID NO: 1-12 and 25; and
 - (f) sequences that are 20-mers of a sequence of SEQ ID NO: 1-12 and 25.
3. An isolated polynucleotide comprising a sequence selected from the group consisting of:
 - (a) sequences having at least 75% identity to a sequence of SEQ ID NO: 1-12 and 25;
 - (b) sequences having at least 90% identity to a sequence of SEQ ID NO: 1-12 and 25;
 - (c) sequences having at least 95% identity to a sequence of SEQ ID NO: 1-12 and 25;
 - (d) sequences having at least 98% identity to a sequence of SEQ ID NO: 1-12 and 25; and
 - (e) sequences that hybridize to a sequence of SEQ ID NO: 1-12 and 25 under stringent hybridization conditions,wherein the polynucleotide encodes a polypeptide having substantially the same functional properties as a polypeptide encoded by SEQ ID NO: 1-12 or 25.
4. An isolated oligonucleotide probe or primer comprising at least 10 contiguous residues complementary to 10 contiguous residues of a nucleotide sequence recited in claim 1.
5. A kit comprising a plurality of oligonucleotide probes or primers of claim 4.

6. An isolated polypeptide encoded by a polynucleotide of claim 1.
7. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of: sequences recited in SEQ ID NO: 13-24 and 26.
8. The isolated polypeptide of claim 7, wherein the polypeptide is in multimeric form.
9. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - (a) sequences having at least 75% identity to a sequence of SEQ ID NO: 13-24 and 26;
 - (b) sequences having at least 90% identity to a sequence of SEQ ID NO: 13-24 and 26;
 - (c) sequences having at least 95% identity to a sequence of SEQ ID NO: 13-24 and 26;
 - (d) sequences having at least 98% identity to a sequence of SEQ ID NO: 13-24; and
 - (e) functional portions of a sequence of SEQ ID NO: 13-24 and 26,wherein the polypeptide possesses an ability to bind ice crystals.
10. An isolated polynucleotide that encodes a polypeptide of any one of claims 7-9.
11. A genetic construct comprising a polynucleotide of any one of claims 1-3.
12. A transgenic cell comprising a genetic construct according to claim 11.
13. A genetic construct comprising, in the 5'-3' direction:
 - (a) a gene promoter sequence;
 - (b) a polynucleotide sequence comprising at least one of the following: (1) a polynucleotide coding for at least a functional portion of a polypeptide encoded by a polynucleotide of any one of claims 1-3; and (2) a

polynucleotide comprising a non-coding region of a polynucleotide of any one of claims 1-3; and

(c) a gene termination sequence.

14. The genetic construct of claim 13 wherein the polynucleotide is in a sense orientation.

15. The genetic construct of claim 13 wherein the polynucleotide is in an anti-sense orientation.

16. A transgenic cell comprising a genetic construct of claim 13.

17. An organism comprising a transgenic cell according to claim 16, or progeny thereof.

18. A method for modulating cold tolerance in an organism, comprising stably incorporating into the genome of the organism at least one polynucleotide of any one of claims 1-3.

19. The method of claim 18, wherein the organism is selected from the group consisting of: plants; mammals; insects; fungi; archaea; and bacteria.

20. The method of claim 18, comprising stably incorporating into the genome of the organism a genetic construct of claim 13.

21. A method for producing a plant having altered cold tolerance, comprising:

- (a) transforming a plant cell with a genetic construct of claim 13 to provide a transgenic cell; and
- (b) cultivating the transgenic cell under conditions conducive to regeneration and mature plant growth.

22. The method of claim 21 wherein the plant is selected from the group consisting of: *Lolium* species; *Festuca* species; and *Eucalyptus* species.

23. A method for modifying the activity of an antifreeze protein in an organism comprising stably incorporating into the genome of the organism a genetic construct of claim 13.

24. A method for modifying the activity of an antifreeze protein in an organism, comprising introducing into cells of the organism double stranded RNA corresponding to a polynucleotide of any one of claims 1-3, thereby inhibiting expression of a polypeptide encoded by the polynucleotide.

25. A method for cryopreserving a cell or tissue, comprising contacting the cell or tissue with at least one polypeptide of any one of claims 7-9.

26. A food additive comprising a polypeptide of any one of claims 7-9.

27. A frozen food product comprising a food additive of claim 25.

28. A method for decreasing an amount of time required to dehydrate a composition comprising contacting the composition with a polypeptide of any one of claims 7-9.

29. A composition comprising a polypeptide of any one of claims 7-9 and a physiologically acceptable carrier.

30. A method for the treatment of a disorder characterized by the presence of unwanted biocrystals in a patient, comprising administering to the patient a composition of claim 29.

31. A method for preserving the viability of a molecular biology reagent, comprising contacting the reagent with a polypeptide of any one of claims 7-9.

32. A method for destroying unwanted tissue in a patient, comprising:

(a) perfusing the tissue with a solution comprising a polypeptide of any one of claims 7-9; and

(b) freezing the tissue for a period of time sufficient to mortally damage cells within the tissue.

33. The method of claim 32, wherein the undesirable tissue is tumor tissue.
34. A composition comprising at least one polypeptide of any one of claims 7-9 and an agricultural carrier.
35. A method for protecting a plant from damage due to frost or freezing, comprising applying a composition of claim 34 to the plant.

1/5

Fig. 1

MAKCWQLLLFLALLLPAASAASCHPDDLIALRDFAGNLRGGGVLLRAALPGASSCCGWEGV 60
GCDGASGCVKSFQILLKGLTAAGRSLGKAFTHMPLHVKPSQGTLDEHNTITGINNTVRS 120
GSNNVVSNDNTVISGNNNVVSGSHNTVVFGGDNFISGSYHVVS¹GNHHVVTDNKNAVSGD 180
HNTVSGSQNTVSGNHQIVSGSHSTVSGNHNTVSGRNNSVYGNNNIVSGSNHV²VYGNNKVV 240
TGG 243

Fig. 2

MAKCWQLLLFLAFLPAASAASRHPDDLRALQDFAGNLRGGGVLLRAALSGGSCCDWEGA 60
GCDGASGRVTSFQILLKGLTTAGRSLGKAFTNMPLHVKSSQGTLDEHNTITGINNTVKS 120
GSNNVVSNDNTVISGNNNVVSGSHNTVVFGGDNFLSGSNHVVS¹GNHHVVTDNKNAVSGD 180
HNTVSGSQNTVSGNHIIISASHSTISGNHNTVSGSNFVSGNNNIVSGSNHV²VYGNNKVV 240
TGG 243

Fig. 3

MPEYMAKCCMLLVFLGFILOVAGATSWSCHHDDLHALRGLAENLSGKGAVRLRAAWSGAS 60
CCSWEGVGCETASGRVVALRLPKRGLGGIIPSSIGELDHLRYLDLSGNSLVGEVPKSLQI 120
RLKSLTTDSQSLGMGSINMLLVSSRRTLDEEPNTISGTNNSVGSGSNNVVSNDNTVVS 180
GNNNHVSGSNNTVVTGSDNTVVGSNHVVSGTKHIVTDNNNVSGNDNNVSGSFHTVSGEH 240
NTVSGSNNTVSGSNHIVSGSNKVVDG 267

2/5

Fig. 4

<u>MPEYMAKCCMLLLLLLAFILLOVAGATSWSCHHDDLRLALRGFAENLSGKGAVRLRAAWSGA</u>	60
<u>SCCSWEGVGCETASGRVAALRLPKRGLGGTIPSSIGELDHLRCLDLSGNSLVGKVPKSLQ</u>	120
IRLXSLSTDGQSLGMSGINTLLHVSSNRRTLDE <u>EPNTISGTNNSVSGSGSNVVS</u> <u>GNDNTV</u>	180
<u>ISGNNNHVSGSNNTVVTGSDNTLVGSNHVVS</u> <u>GTKHI</u> <u>VTDNNNVVS</u> <u>GNDNNVS</u> <u>GSFHTVSG</u>	240
<u>EHNTVSGSNNTVSGSNHVVS</u> <u>GSNKVVTDG</u>	269

Fig. 5

<u>MAKCWLLLLFLVFLLLAMSATSCHLDDLRLALRGFVGNLNGGGALLRGTWSGSSCCDWEGV</u>	60
<u>GCDGTSGRVTALRLPISLEDCCGKLKSLNLANERLVGTIPSWIGELDHHCYLVLS</u> <u>DNLSLVG</u>	120
<u>KAPNSLHNSLQIRLKGLATAGRSLGMAFANMPLHVKG</u> <u>NRRTLDEQTNTIHGTNNTV</u> <u>RSGN</u>	180
<u>DNAVSGNDNTVICGNNNTVSGSNNTIASGSDNIVTGSNHIVCGTKHIITDNNNDVSGNDN</u>	240
<u>NVSGSFHTVSGSHNTVSGSNNTVSGSNHVVS</u> <u>GSNKLVTDG</u>	281

Fig. 6

<u>MAKCWLLLLFLVLLPAASATSCHPDDLRLALRGFVGNLNGGGVLLHGAWSGSLCCAWE</u> <u>GV</u>	60
<u>GCDGTSGRVTALRLPISLKDCGKLKSLNLANDR</u> <u>LVGTIPSWIGELDHL</u> <u>CYLVLS</u> <u>DNLSLVG</u>	120
<u>KVPNSLQIRLKGLATAGRSLGMAFANMPLHVKG</u> <u>NRRTLDEQTNTIQGTNNTV</u> <u>RSGNDNAV</u>	180
<u>SGNDNTVICGNNNTVSGSNNTIVSGSDNIVTGSNQVVC</u> <u>GTKHIITDNNNDVSGNDNNVSG</u>	240
<u>SSHTVSGSHNTVSGSNNTVSGSNHVVS</u> <u>GSNKVVTDG</u>	277

3/5

Fig. 7

<u>MAKCWLLLLLFLVFLLLAVCATSCHPDDLRLALRGFVGNLNGGGVLLRETWSGSSCCAWEGV</u>	60
<u>GCDGTSGRVTALRLPISLED CGKLKSLNLANERLVGTIPSWIGELDHHCYFVLSDNSLVG</u>	120
<u>KVPNSLQIRLKGLATAGRSLGMAFANMPLHVKGNNRRTLDE</u> <u>QTNTIHGTNNTVRS GNDNAV</u>	180
<u>SGNDNTVMCGNNNTVSGSNNTISSGSDNIVTGSNHIVCGTKHII TDNNNDVSGNDNNVSG</u>	240
<u>SFHTVSGSHNTVSGSNNTVSGSNHVVS GSNKVV TG</u> DE	277

Fig. 8

<u>MGLLLLLFLAFL</u> <u>LPVACAATSSCHPDDLRLALRGFAKNLGGGGVLLRTAWSGTSCCVWEGVG</u>	60
<u>CNGASGRVTTLWLPRRGLAGTITGASLAGLARLESINLANNRVLVGTIPSWIGELDHLLYL</u>	120
<u>DLSHNSLVGELPNLKGLTTTGHLLGMAFTSMPLDVKPNRRTLAV</u> <u>QPNTISGTNNSVL SGR</u>	180
<u>NNTVSGNDNTVISGNNNTVSGSFNTVVTGSDNVL TGSNHVVS GRNHIVTDNNNAVSGDDN</u>	240
<u>NVSGSFHKVSGSHNTVSGSNNTVSGRNHVVS GSNKVV TG</u> G	280

Fig. 9

<u>MGLLLLLFLGFL</u> <u>LPAAACAATSSCHPDDLRLALRGFAKNVGGGGVLLRTAWSGTSCCVWEGVG</u>	60
<u>CNGASGRITTLWLPRRGLAGTITGASLAGLARLESINLANNRVLVGTIPSWIGELDHLLYL</u>	120
<u>DLSHNSLVGELPNRL</u> <u>QIRLKGLTTTGHLLGMAFTNMPLDVKRNRTLAI</u> <u>QPNTISGTNNL</u>	180
<u>VLSGRNNAVSGNDNTVISENNNTVSGSFNTVITGSDNVL TGSNHVVS GRSHIVTDNNNSV</u>	240
<u>SGDDNNVSGSFHKVSGSHNTVSGSNNTVSGRNHVVS GSNKIV TG</u> G	285

4/5

Fig. 10

<u>MAKCLMLLLSFAFLLSVAGTATATPCHRDDLRLRGFAENLGGGGAISLRAAWSGASCCD</u>	60
<u>WEGVGCDGASGRVTALWLPRSGLTGPIPSWICQLHHLRYLDLSGNALVGEVPKNLQVQLK</u>	120
GITNMPLHVMRNRRLDE <u>QPNTISGSNNTVRSGSKNVLAGNDNTVISGDNNSVSGSNNTV</u>	180
<u>VSGNDNTVTGSNHVVSGTNHIVTDNNNNVSGNDNNVSGSFHTVSGGHNTVSGSNNTVSGS</u>	240
<u>NHVVSGSNKVVTD</u> A	254

Fig. 11

<u>MAKCLMLLLSFAFLLSAAGTATATPCHRDDLRLRGFAENLGGGGALSRLAAWSGASCCD</u>	60
<u>WEGVGCDGASGRVTALWLPRSGLTGPIPSWICQLHHLRYLDLSGNALVGEVPKNLQVQLK</u>	120
GLTAAGRSGFTNMPLHVMRNRRLDE <u>QPNTISGSNNTVRSGSKNVVAGNDNTVISGDNNNS</u>	180
<u>VSGSNNTVVS GSDNTVTGSNHVVSGTNHIVTDNNNNVSGNDNNVSGSFHTVSGGHNTVSG</u>	240
<u>SNNTVSGSNHVVSGSNKVVTD</u> A	262

Fig. 12

<u>MAKCLMLLLSFAFLLSAAGTATATATPCHRDDLRLRGFAENLGGGGALSRLAAWSGASC</u>	60
<u>CDWEGVGCDGASGRVTALWLPRSGLTGPIPSWIFQLHHLRYLDLSGNALVGEVPKNLQVQ</u>	120
LKGITNMPLHVMRNRRLDE <u>QPNTISGSNNTVRSGSKNVLAGNDNTVISGDNNSVSGSNN</u>	180
<u>TVVSGNDNTVTGSNHVVSGTNHIVTDNNNNVSGNDNNVSGSFHTVSGGHNTVSGSNNTVS</u>	240
<u>GSNHVVSGSNKVVTD</u> A	256

5/5

Fig. 13

<u>MAKCWLLLLFLVFLLLAMSATSCHLDDLRALRGFVGNLNGGGALLRGTWSGSSCCDWEGV</u>	60
<u>GCDGTSGRVTALRLPISLEDCCGLKSLNLANERLVGTIPSWIGELDHHCYLVLSDNSLVG</u>	120
<u>KAPNSLHNSLQIRLKGLATAGRSLGMAFANMPLHVKGNRRTLDEQTNTIHGTNNTVRSNG</u>	180
<u>DNAVSGNDNTVICGNNNTVSGSNNTIASGSDNIVTGSNHIVCGTKHIITDNNNDVSGNDN</u>	240
<u>NVSGSFHTVSGSHNTVSGSNNTVSGSNHVVSGSNKVVTGDE</u>	281

SEQUENCE LISTING

<110> Demmer, Jeroen
Shenk, Michael Andrew
Hall, Claire
Fish, Steven A

<120> Compositions isolated from forage
grasses and methods for their use.

<130> JC220038/142

<150> 60/409,557

<151> 2002-09-09

<160> 44

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 841

<212> DNA

<213> *Lolium perenne*

<400> 1

ggatgggtttg	tgtatggata	tatcatatat	agcataccgc	agctagctca	gtccatggcg	60
aaatgctggc	agctgctgct	cttcttggca	ctcctcttgc	cggcggcgag	cgccgcgtcg	120
tgccaccctg	atgacctcta	tgccctgcgg	gacttcgccg	gcaacctcag	aggcgggggc	180
gtcctcctcc	gcgccgcctt	gcccggcgcc	tcgtgctgcg	gctgggaagg	tgtgggctgc	240
gacggcgcaa	gcggctgcgt	caagagcttc	cagatatggc	tcaaagggt	caccgcccgt	300
ggccgttcac	tgggtaaggc	gttcactcac	atgccattac	atgtgaagcc	tagccaagga	360
acactcgacg	aagaccacaa	tacaataact	gggatcaaca	atactgtcag	atccgggagc	420
aacaatgttg	tttctgggaa	cgataacact	gtcatatccg	ggaacaacaa	cgctcgtgtcc	480
gggagccaca	acaccgtcgt	atttgggggt	gacaacttca	taagtggag	ttaccatgtc	540
gtatctggga	accaccatgt	tgtgactgac	aacaagaatg	ccgtatccgg	ggaccacaat	600
actgtatctg	gaagccaaaa	taccgtatcc	gggaaccacc	agatcgtatc	tgggagccac	660
agtaccgtat	ccgggaacca	caatacggta	tctgggagaa	acaattccgt	atatgggaac	720
aacaatatgg	tatctgggag	caaccatgtt	gtatatggga	acaacaaagt	cgtgacagga	780
ggttaataat	ctgtcactag	attgttttaa	tgcatcttct	cggttcagtg	taaaaaaaaa	840
a						841

<210> 2

<211> 959

<212> DNA

<213> *Festuca arundinacea*

<400> 2

ggcgacactt	gcttggattc	caatcaagg	ttcgtgctgg	tttgtgtatg	gatatatagc	60
ataccgcagc	tagctcaatt	catggcaaaa	tgctggcagc	tgctactctt	cttggcattc	120
ctcttgccgg	cggcgagcgc	cgcgctcacg	caccctgatg	acctccgcgc	cctgcaggac	180
ttcgccggca	acctcagagg	cgggggcggt	gtcctccgcg	cgecttggc	cgccggctca	240
tgctgcgact	gggaagggtg	gggctgagac	ggtgcaagtg	gccgcgtcac	gagtttccag	300
atattgctca	aagggtcac	caccgctggc	cgttcactgg	gtaaggcggt	cactaacatg	360
ccattacatg	tgaagtctag	ccaaggaaca	ctcgaagaag	aacacaatac	aataactggg	420
atcaacaata	ctgtcaaatc	cgggagcaac	aatgttgttt	ctgggaacga	taacactgtc	480
atatccggga	acaacaacgt	cggtgccggg	agccacaaca	ccgtcgtatt	tgggggtgac	540
aatttcctaa	gcggtagcaa	ccatgtcgta	tctgggaacc	accatgtcgt	gactgacaac	600
agaatgccg	tatccgggga	ccacaatact	gtatctggaa	gccaaaatac	cgatccggg	660
aaccacata	tcatactgc	gagccacagt	accatatccg	ggaaccacaa	taccgtatcc	720
gggagcaaca	atttctgtat	tgggaacaac	aatatgtgat	ctgggagcaa	ccatgtcgta	780
tatgggaaca	acaaggtggg	gacaggaggt	taataatttg	tcactggatt	gtttccatgc	840
atgttctcgg	ttcagtgtag	ctcacgatca	cttgggtggg	ccaatcacgt	tatgtaactt	900

catgtaagca taatTTTTcg tgctTTTaat aaaacttccc tacagataaa aaaaaaaaaa 959

<210> 3
 <211> 980
 <212> DNA
 <213> *Lolium perenne*

<400> 3
 gcttgcattc caatcaaggt ttcttgttca atccatgcct gaatacatgg caaagtgttg 60
 catgctgctg gtcttcttgg gggtcatctt gcagggtggca ggagcaacgt cgtggctcgtg 120
 ccaccacgac gacctccacg cgttgagggg cctcgctgag aacctaaagc gcaaaggagc 180
 cgtccgcctc cgcgcgcgat gggtccggcg ctcattgctg agctgggaag gtgtgggatg 240
 cgaacacagca agcggccgcg tcgtggcggt gcggctcccc aagcgcggcc ttggagggat 300
 catcccatcg tcgattgggt agcttgatca ctttcgctat ttggatctct cgggtaattc 360
 atttggttgg gagggtaccaa aaagtgttga gatacggctc aagagcctca ccactgacag 420
 ccagtcactc ggtatgggtt ccattaacat gctattgcat gtgagcagta gaagaacgct 480
 cgatgaagaa ccaaatataa tatcaggggac caacaatagt gttggatcag ggagcaacaa 540
 tgttgtttcc gggaatgaca acacgggtcgt atctgggaat aacaacctat tgtctgggag 600
 caacaacact gttgtaactg gaagtgacaa tactgtagt ggtagcaacc atgtcgtatc 660
 agggacaaag catattgtta ctgataacaa taatgttcta tccgggaacg acaataatgt 720
 gtctggaagc ttccatactg tatcagggga gcacaatacc gtatccggga gcaacaatac 780
 tgtatccggg agcaaccata tcgtatcttg gagcaacaaa gtcgtaacag atgggtaata 840
 ttctgttagt gcaggattgc ttccatcttc ccaagttcag tgtagcttac aatcaataga 900
 tggagacaat caggttatgt aacttcagga tatggcatac ttttccttta aataaagctt 960
 cccctttacat aaaaaaaaaa 980

<210> 4
 <211> 996
 <212> DNA
 <213> *Festuca arundinacea*

<400> 4
 gacatagctt gcattccaat caaggtttct tgttcaatcc atgcctgaat acatggcaaa 60
 gtgttgcatt ctgctgctcc tcttggcctt catcctcttg cagggtggccg gagcaacgtc 120
 gtggctgctg caccacgacg acctccgcgc attgaggggc ttcgccgaga acctaaagcg 180
 caaaggagcc gtccgcctcc gcgcgcgatg tcctggcgcc tcattgctga gctgggaagg 240
 tgtgggatgc gaaacagcaa gcggccgcgt cgcggcggtg cggctcccca agcgcggcct 300
 tggagggacc atcccatcgt cgatttggtg gcttgatcac cttcgttgtt tggatctctc 360
 gggttaattca ttggttggga aggtaccaaa aagtgttcag atacggctct agagcctctc 420
 cactgatggc cagtcaactc gtatgggttc catcaacag ctattgcatg tgagcagtaa 480
 cagaagaacc ctcgatgaag aaccaaatat aatatcagg accaacaata gtgttggatc 540
 agggagcaac aatgttgttt ccgggaatga caacacggtc atatctggga ataacaacca 600
 tgtgtcttgg agcaacaaca ctgttgaac tggaaagtac aacactttat ttggtagcaa 660
 ccatgtctga tcagggacaa agcatattgt tactgataac aataatgttg tatccgggaa 720
 cgacaataat gtgtctggga gcttccatac tgtatcagg gagcacaata ccgtatcttg 780
 gagcaacaac actgtatccg ggagcaacca tgtcgtatct ggaagcaaca aagtcgtaac 840
 agatgggtta tattctgtag gtgcaggatt gcttccatct tcccaagttc agtgtagctc 900
 ataatacaatt gatggagaca atcacgitat gtaacttcag gatatggcat acttttcctt 960
 taaataaagc ttccctttac ataaaaaaaaa aaaaaa 996

<210> 5
 <211> 1084
 <212> DNA
 <213> *Lolium perenne*

<400> 5
 gacttgcatt ccaaaaaggt ttcttgcata cacgtattta gaacaccaga acttaatcca 60
 tggcgaaatg ttggctgctg ctgctcttct tgggtgttct cttgctggcc atgagcgcg 120
 cgtcgtgccca cctggatgac ctccgcgcgc tgcggggcct tgcgggaac ctcaatggcg 180
 ggggtgccct tctccgtgga acatggctctg gctcctcatg ctgcgattgg gaagggtgtg 240
 gctgcgatgg tacaagcggc cgcgtcacgg cgttgccggt tccgattagc ctcgaggact 300
 gcggtaagct caagtgcctc aaccttgcca acgaaagatt ggttggcacc atcccgtcgt 360
 ggattgggtg gcttgaccac cattgctact tggttctctc ggataattca ttggttggta 420
 aggcacccaa tagtttgcac aatagtttgc agataagact caagggcctc gccaccgctg 480

gtcgttcact	aggtatggct	ttcgctaaca	tgccattgca	tgtgaagggg	aaccgaagaa	540
ccctcgacga	acaaacaaat	acaatacatg	ggaccaacaa	cactgttaga	tctgggaacg	600
acaatgctgt	ttctgggaac	gacaacactg	tcatatgtgg	gaacaacaac	actgtgtctg	660
ggagcaacaa	caccattgca	tctggcagtg	acaatatcgt	aactggcagc	aaccatattg	720
tatgtgggac	caaacatata	ataactgata	acaacaatga	cgtatccggc	aatgataata	780
atgtatctgg	gagcttccat	actgtatccg	ggagccacaa	tactgtatct	ggaagtaaca	840
acactgtatc	tggaagcaac	catgtcgtat	ctggaagcaa	caaactcgtg	acaggagatg	900
aatgatttgt	caggggattg	cttccatctt	tcctaaagga	gctctcacc	tagtccaagt	960
tcggtgcagc	tcacaatcac	ttggtaggga	caatcgagtt	atgtaacttc	atggatatag	1020
catcattctc	cctgttttaa	tatactttcc	tgaaaatatc	ttacataaat	gctgaaaaaa	1080
aaaa						1084

<210> 6

<211> 1230

<212> DNA

<213> Festuca arundinacea

<400> 6

actcacttgc	attccaaaaa	aggtttcttg	ctgagttggt	tgcgtaacaca	taattagaac	60
accacaactc	aatccatggc	gaaatgttgg	ctgctgtctg	tcttcttggg	ggtcctcttg	120
ccggccgcga	gcgcgacgtc	gtgccacccc	gatgacctcc	gcgcgctgcg	tggctttgtc	180
gggaacctca	atggcggggg	tgtccttctt	catggagcat	gggtccggctc	cttatgttgc	240
gcctgggaag	gcgtgggctg	cgatggtaca	agcggccgcg	tcacggcatt	gcggcttccg	300
attagcctca	aggattgcgg	caagctcaag	tcgctcaacc	ttgccaacga	tagactgggt	360
ggcaccatcc	cgtcgtggat	tgggtgagctt	gaccaccttt	gctacttggg	tctctcggat	420
aattcattgg	ttggttaagg	acccaatagt	ttgcagataa	gactcaaggg	cctcgccacc	480
gctggctcgt	cactaggtat	ggctttcgtc	aacatgccat	tgcatgtgaa	gggcaaccga	540
agaacactcg	acgaacaaac	aaatacaata	caggggacca	acaacacagt	tagatctggg	600
aacgacaatg	cagtttcttg	gaacgacaac	actgtcatat	gtgggaacaa	caacactgtg	660
tctggggagca	acaatactat	tgtatctggg	agtgaacata	tcgtaactgg	tagcaaccag	720
gttgatgtgt	ggaccaaaca	tatcataact	gataacaaca	atgacgtatc	cgggaacgat	780
aacaactgtat	ctgggagttc	ccatactgta	tccgggagcc	acaatactgt	atccgggagt	840
aacaacactg	tatctggaag	caaccatgtc	gtatctggga	gcaacaaagt	cgtgacagga	900
gatgaatgat	ttgtcagggg	atcgtttcca	tcttccctaa	aggagcactc	acccttgtcc	960
aagttcagtg	tagctcacag	tcacttggtg	gggacaatcg	agttatgtaa	cttcatggat	1020
atagcctcat	ttttctagt	taaatatact	ttcctgaaaa	tatcttacat	acatgctgat	1080
ataaatataa	aggcggtctt	catgctactg	atgtatacca	agcgtgtttt	cttggtacg	1140
aatttgcag	gacatgcagc	tgatgtagac	caagcgtgtt	atatgtgata	tgtgatgctt	1200
taataaacat	atTTTTgttg	aaaaaaaaaa				1230

<210> 7

<211> 1212

<212> DNA

<213> Lolium perenne

<400> 7

gcttgcatc	caaaaagggt	tcttgcgtac	acgtatttag	aagaccacaa	cttaatccat	60
ggcgaaatgt	tggctgctgc	tgctcttctt	gggtgttctc	ttgctggccg	tgtgcgcgac	120
atcgtgcccac	ccagatgacc	tccgcgcgct	gcggggcttt	gtcgggaacc	tcaatggcgg	180
gggtgtcctt	ctccgtgaaa	catggtctgg	ctcctcatgc	tgcgcctggg	aaggtgtggg	240
ctgcgatgg	acaagcgggc	gcgtcacggc	gttgcggtt	ccgattagcc	tcgaggattg	300
cggttaagctc	aagtcgctca	accttgccaa	cgaaagattg	gttggcacca	tcccgtcgtg	360
gattgggtgag	cttgaccacc	attgtactct	cgttctctcg	gacaattcat	tggttggtaa	420
ggtacccaat	agtttgcaga	taagactcaa	aggcctcgcc	accgctgggtc	gttactagg	480
tatggctttc	gctaacatgc	cattgcatgt	gaaggggaac	cgaagaacac	tcgacgaaca	540
aacaaatata	atacatggta	ccaacaacac	tgtagatct	gggaacgaca	atgtgttttc	600
tgggaacgac	aacacagtca	tgtgtgggaa	caacaacaca	gtgtctggga	gcaacaacac	660
catttcatct	ggcagtgaca	atatcgtaac	tggtagcaac	catattgtat	gtgggaccaa	720
acatatcata	actgataaca	acaatgacgt	atccggcaat	gataacaatg	tatctgggag	780
cttccatact	gtatccggga	gccacaatac	tgtatctggg	agtaacaaca	ctgtatctgg	840
aagcaacctat	gtcgtatctg	gaagcaacaa	agtcgtgaca	ggagatgaat	gatttgtcag	900
gggattgttc	catcttccct	aaaggagctc	tacccttgt	ccaagttcag	tgtcagctcac	960
aatcacattg	taggggcaat	cgagttatgt	aacttcatgg	atatagcatc	attttcttat	1020
agtttaaata	tattttcctg	aaaatatctt	acatacatgc	tgatatgaat	atcaaaggcg	1080

gctttcacgc	agctgatgta	tacgtgtttt	cttatgtacg	aatttgcatt	gacatgcaga	1140
gctgatgtag	accaagcttg	ttctatgtaa	tatgtgatgc	attaaacata	tttttgttga	1200
ataaaaaaaa	aa					1212

<210> 8

<211> 1064

<212> DNA

<213> *Lolium perenne*

<400> 8

gcacttactt	gcatttctaaa	ataggttttct	tgcataccac	aactagctga	atccatgggg	60
ctgttgctgc	tcttcttggc	gttcctcttg	ccagtggcat	gcgcggcaac	gtcagattgc	120
caccccgatg	acctccgtgc	cctgcggggc	tttgccaaga	accttggcgg	cggaggcgtc	180
ctcctccgca	ccgcgtggtc	cggcacctcg	tgctgcgtct	gggaagggtg	tggctgcaat	240
ggcgcgagcg	gccgcgtcac	cacgttgttg	ctccctaggc	gtggccttgc	ggggaccatc	300
acaggagcat	ccttggccgg	cctcgcgcgg	ctggagtcac	tcaaccttgc	caacaacaga	360
ctggctcggca	ccatcccatc	gtggattggg	gagcttgacc	accttctcta	cttggatctc	420
tcacataatt	catttggttg	cgagctgccc	aacctcaagg	gcctcaccac	cacaggtcat	480
ttactaggtg	tggctttcac	tagcatgcca	ttggatgtga	agcctaacag	aagaactctc	540
gccgtacaac	caaatacaat	atctgggacc	aacaactcgg	tcttatctgg	gcgaacaat	600
actgtgtctg	ggaatgacaa	cactgtcata	tcggggaaca	acaatactgt	gtctggggagc	660
ttcaacaccg	tcgtaacggg	aagtgacaat	gtcttaactg	ggagcaacca	tgctgtatct	720
gggagaaacc	atatgttaac	tgacaacaac	aatgctgtat	ctggggacga	caataatgtg	780
tcggggagct	tccataaagt	atctggaagt	cacaatacgg	tatctggggg	caacaatacc	840
gtatccggga	gaaaccatgt	cgtatctggg	agcaacaaag	tcgtgacagg	aggttaatga	900
tatgttagtg	gattgtttcc	atcttcccta	agggatctca	cgtacttgac	aaagttcagt	960
gtagcactca	atcacttggt	ggggacaatc	gggttatgta	acgtcatgga	tatagcatac	1020
gtacttttcc	tactttaaat	aagaactttc	ctataaaaaa	aaaa		1064

<210> 9

<211> 1246

<212> DNA

<213> *Festuca arundinacea*

<400> 9

gcttacttgc	attctaaaaat	aggttttcttg	cataccacag	ctagctgaat	ccatggggct	60
gttgctgctc	ttcttggggg	tcctcttgcc	agcagcgtgc	gcggcaacgt	cgagttgcca	120
ccccgatgac	ctccgtgccc	tgccggggctt	tgccaagaac	gttgggtggcg	gaggcgtcct	180
cctccgcacc	gcgttggtccg	gcacctcgtg	ctgcgtcttg	gaagggtgtg	gatgcaatgg	240
cgcgagcggc	cgcatacaca	cgttgtgggt	ccctaggcgt	ggccttgccg	ggaccatcac	300
aggagcatcc	ttggccggcc	tcgcgaggct	ggagtcactc	aaccttgcca	acaacagact	360
ggtcggcacc	atcccatcgt	ggattgggtga	gcttgaccac	cttctctact	tggatctctc	420
acataattca	ttgggtggcg	agctgcccac	ccgtttgcag	atacggctca	agggcctcac	480
caccacaggt	catttactag	gtatggcctt	cactaacatg	ccattggatg	tgaagcgtaa	540
cagaagaact	ctcgccatac	aaccaaatc	aatatctggg	accaacaact	tggcttctat	600
tgggcgaaac	aatgtagttt	ctgggaatga	caacactgtc	atatcggaga	acaacaatac	660
tgtgtctggt	agcttcaaca	ccgtcataac	gggaagtgc	aatgtcttaa	ctgggagcaa	720
ccatgtcgtg	tctggggagaa	gccatattgt	aactgacaac	aacaattctg	tatctggggg	780
cgacaataat	gtgtccggga	gcttccataa	agtatccgga	agtcacaata	cggatcttgg	840
gagcaacaat	accgtatcgg	ggagaaaacca	tgctgtatct	gggagcaaca	aaatcgtgac	900
aggagggttaa	tgatattgta	gtggattggt	tccatcttcc	ctaagggatc	tcacgtactt	960
gacagagttc	agtgtagcac	tcaatcactt	ggtggggaca	atcgggttat	gtaacttcat	1020
gggataatc	afacctttcc	tactttaaat	aaaaactttc	ctataatatc	ttacagacct	1080
gagtatcaac	agtggcttgg	agctaattga	gaccaatcat	atttgcttat	gtacaaaattc	1140
gaattgtgga	tggtgacatg	tggtgattat	ttctcgcttt	ctattctgtg	cgatgtttga	1200
tgctttatta	tactgattag	gttgtggatc	acagggaaaa	aaaaaa		1246

<210> 10

<211> 1008

<212> DNA

<213> *Lolium perenne*

<400> 10

caacaacact	tgcgagtcac	ttgcattgca	ggaaagggtt	cttattgaat	ccatctatag	60
------------	------------	------------	------------	------------	------------	----

catagcactg	ctgaatccat	ggcgaaatgc	ttgatgctgc	tgctctcctt	cgcgcttcctc	120
ttgtcgggtg	ccggcacggc	gacggcgacg	ccatgccacc	gcgatgacct	tcgcgcgctg	180
cggggcttcg	ctgagaacct	gggcggcggc	ggcgcaatca	gcctccgcgc	cgcggtgtca	240
ggcgccctcat	gctgcgattg	ggaaggcggt	ggctgcgacg	gtgccagcgg	ccgtgtcacg	300
gctttgtggc	tccccaggag	cggcctcacg	gggccaatcc	cgatcatggat	ttgtcagctt	360
caccacctac	gctacttggg	tctttcaggt	aatgcattgg	ttggcgaggt	acccaagaat	420
ctgcaggtag	agctcaaagg	catcaccaac	atgccatttg	atgtgatgcg	taacagaaga	480
tcactcgacg	agcagcccaa	tacaatttct	gggagcaaca	atactgtcag	atccgggagc	540
aaaaatgttc	ttgctgggaa	tgacaacacc	gtcatatctg	gggacaacaa	tagtgtgtct	600
gggagcaaca	acactgtcgt	aagtgggaat	gacaataccg	taaccggcag	caaccatgtc	660
gtatcaggga	caaaccatat	cgttacagac	aacaacaata	acgtatccgg	gaacgataat	720
aatgtatccg	ggagctttca	taccgtatcc	ggggggcaca	atactgtctc	cgggagcaac	780
aataccgtat	ctgggagcaa	ccacgttgta	tctggaagca	acaaagtcgt	gacagacgct	840
taatgatctg	tcagcgcgat	attgtttcca	ccttaactga	gtcacgcttc	ttgtccaagt	900
tcactgtacc	tcacagtcag	ttggtgcgtt	caatcgcgtt	atgtaacttc	atggatatac	960
catacttttc	ctactatata	taaaatttcc	ctttacataa	aaaaaaaa		1008

<210> 11

<211> 1006

<212> DNA

<213> Festuca arundinacea

<400> 11

ggcaggaaag	gtttcttgtt	gaatccatct	atagcatagc	actgctgaat	ccatggcgaa	60
atgcttgatg	ctgctgctct	ccttcgcgtt	cctcttgtcg	gcggctggca	cgccgacggc	120
gacgccatgc	caccgggatg	acctccgtgc	gctgcggggc	ttcgctgaga	acctgggagg	180
cgccggcgca	ctcagccttc	gcgcgcgctg	gtcaggcgcc	tcagtctgcg	attgggaagg	240
cgttggctgc	gacgggtgca	gcggccgtgt	cacggctttg	tggtctccca	ggagcggcct	300
cacggggcca	atccccatcg	ggatttgtca	gcttcaccac	ctacgctact	tggatctttc	360
aggtaatgca	ttggttggcg	aggtacccaa	gaatctgcag	gtacagctca	aaggcctcac	420
cgctgccggt	cgttcgggtt	tcaccaacat	gccattgcat	gtgatgcgta	acagaagatc	480
actcgacgag	cagcccaata	caatatctgg	gagcaacaat	actgtcagat	ccgggagcaa	540
aaatgttgtt	gctgggaatg	acaacaccgt	catatctggg	gacaacaata	gtgtgtctgg	600
gagcaacaac	actgtcgtaa	gtgggagtga	caataccgta	actggcagca	accatgtcgt	660
atcagggaca	aaccatatcg	ttacagacaa	caacaataac	gtatccggga	acgataataa	720
tgtatccggg	agctttcata	cggtatccgg	ggggcacaat	accgtctctg	ggagcaacaa	780
taccgtatct	gggagcaacc	atgttgtatc	tggaagcaac	aaagtctgta	cagacgctta	840
atgatctgtc	agcgcgatgat	tgtttccacc	ttacttgagc	tcacgttctt	gtccaagttc	900
actgtacctc	acagtcagtt	ggtgcgttca	atcgcgttat	gtaacttcat	ggatataacca	960
tacttttccct	actatatata	aaatttccct	ttaaaaaaaa	aaaaaa		1006

<210> 12

<211> 1007

<212> DNA

<213> Lolium perenne

<400> 12

ggagtcactt	gcattgcatt	gcaggaaagg	tttcttattg	aatccatcta	tagcatagca	60
ctgctgaatc	catggcgaaa	tgcttgatgc	tgcttctctc	cttcgcgttc	ctcttgtcgg	120
cgccgggcac	ggcgacggcg	acggcgacgc	catgccaccg	cgatgacctt	cgcgcgctgc	180
ggggctttcg	tgagaacctg	ggcgggcgcg	gcgcactcag	cctccgcgcc	gcgtggctcag	240
gcgcctcatg	ctgcgattgg	gaaggcggtg	gctgcgacgg	tgccagcggc	cgtgtcacgg	300
ctttgtggct	ccccaggagc	ggcctcacgg	ggccaatccc	gtcatggatt	tttcagcttc	360
accacctacg	ctacttggat	citttcaggta	atgcattggg	tgccgaggta	cccaagaatc	420
tgcagggtaca	gctcaaaggc	atcaccaaca	tgccattgca	tgtgatgcgt	aacagaagat	480
cactcgacga	gcagcccaat	acaatttctg	ggagcaacaa	tactgtcaga	tcggggagca	540
aaaatgttct	tgctgggaat	gacaacaccg	tcatatctgg	ggacaacaat	agtgtgtctg	600
ggagcaacaa	cactgtcgta	agtgggaatg	acaataccgt	aaccggcagc	aacctgtctg	660
tatcagggac	aaaccatatc	gttacagaca	acaacaataa	cgtatccggg	aacgataata	720
atgtatccgg	gagctttcat	accgtatccg	gggggacaaa	tactgtctcc	gggagcaaca	780
ataccgtatc	tgggagcaac	cacgttgatg	ctggaagcaa	caaagtcgtg	acagacgctt	840
aatgatctgt	cagcgcgatga	ttgtttccac	cttaactgag	ctcacgttct	tgtccaagtt	900
cactgtacct	cacagtcagt	tgggtgcgtt	aatcgcgtta	tgttaacttca	tggatataacc	960
atacttttcc	tactatatata	aaaatttccc	tttacataaa	aaaaaa		1007

<210> 13
 <211> 243
 <212> PRT
 <213> Lolium perenne

<400> 13
 Met Ala Lys Cys Trp Gln Leu Leu Leu Phe Leu Ala Leu Leu Leu Pro
 1 5 10 15
 Ala Ala Ser Ala Ala Ser Cys His Pro Asp Asp Leu Tyr Ala Leu Arg
 20 25 30
 Asp Phe Ala Gly Asn Leu Arg Gly Gly Gly Val Leu Leu Arg Ala Ala
 35 40 45
 Leu Pro Gly Ala Ser Cys Cys Gly Trp Glu Gly Val Gly Cys Asp Gly
 50 55 60
 Ala Ser Gly Cys Val Lys Ser Phe Gln Ile Leu Leu Lys Gly Leu Thr
 65 70 75 80
 Ala Ala Gly Arg Ser Leu Gly Lys Ala Phe Thr His Met Pro Leu His
 85 90 95
 Val Lys Pro Ser Gln Gly Thr Leu Asp Glu Asp His Asn Thr Ile Thr
 100 105 110
 Gly Ile Asn Asn Thr Val Arg Ser Gly Ser Asn Asn Val Val Ser Gly
 115 120 125
 Asn Asp Asn Thr Val Ile Ser Gly Asn Asn Asn Val Val Ser Gly Ser
 130 135 140
 His Asn Thr Val Val Phe Gly Gly Asp Asn Phe Ile Ser Gly Ser Tyr
 145 150 155 160
 His Val Val Ser Gly Asn His His Val Val Thr Asp Asn Lys Asn Ala
 165 170 175
 Val Ser Gly Asp His Asn Thr Val Ser Gly Ser Gln Asn Thr Val Ser
 180 185 190
 Gly Asn His Gln Ile Val Ser Gly Ser His Ser Thr Val Ser Gly Asn
 195 200 205
 His Asn Thr Val Ser Gly Arg Asn Asn Ser Val Tyr Gly Asn Asn Asn
 210 215 220
 Ile Val Ser Gly Ser Asn His Val Val Tyr Gly Asn Asn Lys Val Val
 225 230 235 240
 Thr Gly Gly

<210> 14
 <211> 243
 <212> PRT
 <213> Festuca arundinacea

<400> 14
 Met Ala Lys Cys Trp Gln Leu Leu Leu Phe Leu Ala Phe Leu Leu Pro
 1 5 10 15
 Ala Ala Ser Ala Ala Ser Arg His Pro Asp Asp Leu Arg Ala Leu Gln
 20 25 30
 Asp Phe Ala Gly Asn Leu Arg Gly Gly Gly Val Val Leu Arg Ala Ala
 35 40 45
 Leu Ser Gly Gly Ser Cys Cys Asp Trp Glu Gly Ala Gly Cys Asp Gly
 50 55 60
 Ala Ser Gly Arg Val Thr Ser Phe Gln Ile Leu Leu Lys Gly Leu Thr
 65 70 75 80
 Thr Ala Gly Arg Ser Leu Gly Lys Ala Phe Thr Asn Met Pro Leu His
 85 90 95
 Val Lys Ser Ser Gln Gly Thr Leu Asp Glu Glu His Asn Thr Ile Thr
 100 105 110
 Gly Ile Asn Asn Thr Val Lys Ser Gly Ser Asn Asn Val Val Ser Gly
 115 120 125
 Asn Asp Asn Thr Val Ile Ser Gly Asn Asn Asn Val Val Ser Gly Ser
 130 135 140

His Asn Thr Val Val Phe Gly Gly Asp Asn Phe Leu Ser Gly Ser Asn
 145 150 155 160
 His Val Val Ser Gly Asn His His Val Val Thr Asp Asn Lys Asn Ala
 165 170 175
 Val Ser Gly Asp His Asn Thr Val Ser Gly Ser Gln Asn Thr Val Ser
 180 185 190
 Gly Asn His His Ile Ile Ser Ala Ser His Ser Thr Ile Ser Gly Asn
 195 200 205
 His Asn Thr Val Ser Gly Ser Asn Asn Phe Val Ser Gly Asn Asn Asn
 210 215 220
 Ile Val Ser Gly Ser Asn His Val Val Tyr Gly Asn Asn Lys Val Val
 225 230 235 240
 Thr Gly Gly

<210> 15
 <211> 267
 <212> PRT
 <213> *Lolium perenne*

<400> 15
 Met Pro Glu Tyr Met Ala Lys Cys Cys Met Leu Leu Val Phe Leu Gly
 1 5 10 15
 Phe Ile Leu Gln Val Ala Gly Ala Thr Ser Trp Ser Cys His His Asp
 20 25 30
 Asp Leu His Ala Leu Arg Gly Leu Ala Glu Asn Leu Ser Gly Lys Gly
 35 40 45
 Ala Val Arg Leu Arg Ala Ala Trp Ser Gly Ala Ser Cys Cys Ser Trp
 50 55 60
 Glu Gly Val Gly Cys Glu Thr Ala Ser Gly Arg Val Val Ala Leu Arg
 65 70 75 80
 Leu Pro Lys Arg Gly Leu Gly Gly Ile Ile Pro Ser Ser Ile Gly Glu
 85 90 95
 Leu Asp His Leu Arg Tyr Leu Asp Leu Ser Gly Asn Ser Leu Val Gly
 100 105 110
 Glu Val Pro Lys Ser Leu Gln Ile Arg Leu Lys Ser Leu Thr Thr Asp
 115 120 125
 Ser Gln Ser Leu Gly Met Gly Ser Ile Asn Met Leu Leu His Val Ser
 130 135 140
 Ser Arg Arg Thr Leu Asp Glu Glu Pro Asn Thr Ile Ser Gly Thr Asn
 145 150 155 160
 Asn Ser Val Gly Ser Gly Ser Asn Asn Val Val Ser Gly Asn Asp Asn
 165 170 175
 Thr Val Val Ser Gly Asn Asn Asn His Val Ser Gly Ser Asn Asn Thr
 180 185 190
 Val Val Thr Gly Ser Asp Asn Thr Val Val Gly Ser Asn His Val Val
 195 200 205
 Ser Gly Thr Lys His Ile Val Thr Asp Asn Asn Asn Val Val Ser Gly
 210 215 220
 Asn Asp Asn Asn Val Ser Gly Ser Phe His Thr Val Ser Gly Glu His
 225 230 235 240
 Asn Thr Val Ser Gly Ser Asn Asn Thr Val Ser Gly Ser Asn His Ile
 245 250 255
 Val Ser Gly Ser Asn Lys Val Val Thr Asp Gly
 260 265

<210> 16
 <211> 269
 <212> PRT
 <213> *Festuca arundinacea*

<220>
 <221> VARIANT
 <222> (1)...(269)

<223> Xaa = Any Amino Acid

<400> 16

```

Met Pro Glu Tyr Met Ala Lys Cys Cys Met Leu Leu Leu Leu Leu Ala
1      5      10      15
Phe Ile Leu Leu Val Ala Gly Ala Thr Ser Trp Ser Cys His His
20      25      30
Asp Asp Leu Arg Ala Leu Arg Gly Phe Ala Glu Asn Leu Ser Gly Lys
35      40      45
Gly Ala Val Arg Leu Arg Ala Trp Ser Gly Ala Ser Cys Cys Ser
50      55      60
Trp Glu Gly Val Gly Cys Glu Thr Ala Ser Gly Arg Val Ala Ala Leu
65      70      75      80
Arg Leu Pro Lys Arg Gly Leu Gly Gly Thr Ile Pro Ser Ser Ile Gly
85      90      95
Glu Leu Asp His Leu Arg Cys Leu Asp Leu Ser Gly Asn Ser Leu Val
100      105      110
Gly Lys Val Pro Lys Ser Leu Gln Ile Arg Leu Xaa Ser Leu Ser Thr
115      120      125
Asp Gly Gln Ser Leu Gly Met Gly Ser Ile Asn Thr Leu His Val
130      135      140
Ser Ser Asn Arg Arg Thr Leu Asp Glu Glu Pro Asn Thr Ile Ser Gly
145      150      155      160
Thr Asn Asn Ser Val Gly Ser Gly Ser Asn Asn Val Val Ser Gly Asn
165      170      175
Asp Asn Thr Val Ile Ser Gly Asn Asn Asn His Val Ser Gly Ser Asn
180      185      190
Asn Thr Val Val Thr Gly Ser Asp Asn Thr Leu Val Gly Ser Asn His
195      200      205
Val Val Ser Gly Thr Lys His Ile Val Thr Asp Asn Asn Asn Val Val
210      215      220
Ser Gly Asn Asp Asn Asn Val Ser Gly Ser Phe His Thr Val Ser Gly
225      230      235      240
Glu His Asn Thr Val Ser Gly Ser Asn Asn Thr Val Ser Gly Ser Asn
245      250      255
His Val Val Ser Gly Ser Asn Lys Val Val Thr Asp Gly
260      265

```

<210> 17

<211> 281

<212> PRT

<213> Lolium perenne

<400> 17

```

Met Ala Lys Cys Trp Leu Leu Leu Leu Phe Leu Val Phe Leu Leu Leu
1      5      10      15
Ala Met Ser Ala Thr Ser Cys His Leu Asp Asp Leu Arg Ala Leu Arg
20      25      30
Gly Phe Val Gly Asn Leu Asn Gly Gly Gly Ala Leu Leu Arg Gly Thr
35      40      45
Trp Ser Gly Ser Ser Cys Cys Asp Trp Glu Gly Val Gly Cys Asp Gly
50      55      60
Thr Ser Gly Arg Val Thr Ala Leu Arg Leu Pro Ile Ser Leu Glu Asp
65      70      75      80
Cys Gly Lys Leu Lys Ser Leu Asn Leu Ala Asn Glu Arg Leu Val Gly
85      90      95
Thr Ile Pro Ser Trp Ile Gly Glu Leu Asp His His Cys Tyr Leu Val
100      105      110
Leu Ser Asp Asn Ser Leu Val Gly Lys Ala Pro Asn Ser Leu His Asn
115      120      125
Ser Leu Gln Ile Arg Leu Lys Gly Leu Ala Thr Ala Gly Arg Ser Leu
130      135      140
Gly Met Ala Phe Ala Asn Met Pro Leu His Val Lys Gly Asn Arg Arg
145      150      155      160

```

Thr Leu Asp Glu Gln Thr Asn Thr Ile His Gly Thr Asn Asn Thr Val
 165 170 175
 Arg Ser Gly Asn Asp Asn Ala Val Ser Gly Asn Asp Asn Thr Val Ile
 180 185 190
 Cys Gly Asn Asn Asn Thr Val Ser Gly Ser Asn Asn Thr Ile Ala Ser
 195 200 205
 Gly Ser Asp Asn Ile Val Thr Gly Ser Asn His Ile Val Cys Gly Thr
 210 215 220
 Lys His Ile Ile Thr Asp Asn Asn Asn Asp Val Ser Gly Asn Asp Asn
 225 230 235 240
 Asn Val Ser Gly Ser Phe His Thr Val Ser Gly Ser His Asn Thr Val
 245 250 255
 Ser Gly Ser Asn Asn Thr Val Ser Gly Ser Asn His Val Val Ser Gly
 260 265 270
 Ser Asn Lys Leu Val Thr Gly Asp Glu
 275 280

<210> 18
 <211> 277
 <212> PRT
 <213> Festuca arundinacea

<400> 18
 Met Ala Lys Cys Trp Leu Leu Leu Leu Phe Leu Val Val Leu Leu Pro
 1 5 10 15
 Ala Ala Ser Ala Thr Ser Cys His Pro Asp Asp Leu Arg Ala Leu Arg
 20 25 30
 Gly Phe Val Gly Asn Leu Asn Gly Gly Val Leu Leu His Gly Ala
 35 40 45
 Trp Ser Gly Ser Leu Cys Cys Ala Trp Glu Gly Val Gly Cys Asp Gly
 50 55 60
 Thr Ser Gly Arg Val Thr Ala Leu Arg Leu Pro Ile Ser Leu Lys Asp
 65 70 75 80
 Cys Gly Lys Leu Lys Ser Leu Asn Leu Ala Asn Asp Arg Leu Val Gly
 85 90 95
 Thr Ile Pro Ser Trp Ile Gly Glu Leu Asp His Leu Cys Tyr Leu Val
 100 105 110
 Leu Ser Asp Asn Ser Leu Val Gly Lys Val Pro Asn Ser Leu Gln Ile
 115 120 125
 Arg Leu Lys Gly Leu Ala Thr Ala Gly Arg Ser Leu Gly Met Ala Phe
 130 135 140
 Ala Asn Met Pro Leu His Val Lys Gly Asn Arg Arg Thr Leu Asp Glu
 145 150 155 160
 Gln Thr Asn Thr Ile Gln Gly Thr Asn Asn Thr Val Arg Ser Gly Asn
 165 170 175
 Asp Asn Ala Val Ser Gly Asn Asp Asn Thr Val Ile Cys Gly Asn Asn
 180 185 190
 Asn Thr Val Ser Gly Ser Asn Asn Thr Ile Val Ser Gly Ser Asp Asn
 195 200 205
 Ile Val Thr Gly Ser Asn Gln Val Val Cys Gly Thr Lys His Ile Ile
 210 215 220
 Thr Asp Asn Asn Asn Asp Val Ser Gly Asn Asp Asn Asn Val Ser Gly
 225 230 235 240
 Ser Ser His Thr Val Ser Gly Ser His Asn Thr Val Ser Gly Ser Asn
 245 250 255
 Asn Thr Val Ser Gly Ser Asn His Val Val Ser Gly Ser Asn Lys Val
 260 265 270
 Val Thr Gly Asp Glu
 275

<210> 19
 <211> 277
 <212> PRT
 <213> Lolium perenne

<400> 19
 Met Ala Lys Cys Trp Leu Leu Leu Leu Phe Leu Val Phe Leu Leu Leu
 1 5 10 15
 Ala Val Cys Ala Thr Ser Cys His Pro Asp Asp Leu Arg Ala Leu Arg
 20 25 30
 Gly Phe Val Gly Asn Leu Asn Gly Gly Val Leu Leu Arg Glu Thr
 35 40 45
 Trp Ser Gly Ser Ser Cys Cys Ala Trp Glu Gly Val Gly Cys Asp Gly
 50 55 60
 Thr Ser Gly Arg Val Thr Ala Leu Arg Leu Pro Ile Ser Leu Glu Asp
 65 70 75 80
 Cys Gly Lys Leu Lys Ser Leu Asn Leu Ala Asn Glu Arg Leu Val Gly
 85 90 95
 Thr Ile Pro Ser Trp Ile Gly Glu Leu Asp His His Cys Tyr Phe Val
 100 105 110
 Leu Ser Asp Asn Ser Leu Val Gly Lys Val Pro Asn Ser Leu Gln Ile
 115 120 125
 Arg Leu Lys Gly Leu Ala Thr Ala Gly Arg Ser Leu Gly Met Ala Phe
 130 135 140
 Ala Asn Met Pro Leu His Val Lys Gly Asn Arg Arg Thr Leu Asp Glu
 145 150 155 160
 Gln Thr Asn Thr Ile His Gly Thr Asn Asn Thr Val Arg Ser Gly Asn
 165 170 175
 Asp Asn Ala Val Ser Gly Asn Asp Asn Thr Val Met Cys Gly Asn Asn
 180 185 190
 Asn Thr Val Ser Gly Ser Asn Asn Thr Ile Ser Ser Gly Ser Asp Asn
 195 200 205
 Ile Val Thr Gly Ser Asn His Ile Val Cys Gly Thr Lys His Ile Ile
 210 215 220
 Thr Asp Asn Asn Asn Asp Val Ser Gly Asn Asp Asn Asn Val Ser Gly
 225 230 235 240
 Ser Phe His Thr Val Ser Gly Ser His Asn Thr Val Ser Gly Ser Asn
 245 250 255
 Asn Thr Val Ser Gly Ser Asn His Val Val Ser Gly Ser Asn Lys Val
 260 265 270
 Val Thr Gly Asp Glu
 275

<210> 20
 <211> 280
 <212> PRT
 <213> Lolium perenne

<400> 20
 Met Gly Leu Leu Leu Leu Phe Leu Ala Phe Leu Leu Pro Val Ala Cys
 1 5 10 15
 Ala Ala Thr Ser Ser Cys His Pro Asp Asp Leu Arg Ala Leu Arg Gly
 20 25 30
 Phe Ala Lys Asn Leu Gly Gly Gly Gly Val Leu Leu Arg Thr Ala Trp
 35 40 45
 Ser Gly Thr Ser Cys Cys Val Trp Glu Gly Val Gly Cys Asn Gly Ala
 50 55 60
 Ser Gly Arg Val Thr Thr Leu Trp Leu Pro Arg Arg Gly Leu Ala Gly
 65 70 75 80
 Thr Ile Thr Gly Ala Ser Leu Ala Gly Leu Ala Arg Leu Glu Ser Leu
 85 90 95
 Asn Leu Ala Asn Asn Arg Leu Val Gly Thr Ile Pro Ser Trp Ile Gly
 100 105 110
 Glu Leu Asp His Leu Leu Tyr Leu Asp Leu Ser His Asn Ser Leu Val
 115 120 125
 Gly Glu Leu Pro Asn Leu Lys Gly Leu Thr Thr Thr Gly His Leu Leu
 130 135 140
 Gly Met Ala Phe Thr Ser Met Pro Leu Asp Val Lys Pro Asn Arg Arg

145 Thr Leu Ala Val Gln 150 Pro Asn Thr Ile Ser 155 Gly Thr Asn Asn Ser 160 Val
 Leu Ser Gly Arg Asn 165 Asn Asn Thr Val Ser 170 Gly Asn Asp Asn Thr 175 Val Ile
 Ser Gly Asn 180 Asn Asn Thr Val Ser 185 Gly Ser Phe Asn Thr 190 Val Val Thr
 Gly Ser Asp Asn Val Leu Thr Gly Ser Asn His Val Val Ser Gly Arg
 Asn His Ile Val Thr Asp 210 Asn Asn Ala Val 220 Ser Gly Asp Asp Asn 240
 Asn Val Ser Gly Ser Phe His Lys Val Ser Gly Ser His Asn Thr Val
 Ser Gly Ser Asn 245 Asn Thr Val Ser Gly Arg Asn His Val Val Ser Gly
 Ser Asn Lys Val Val Thr Gly Gly 265 270 280

<210> 21
 <211> 285
 <212> PRT
 <213> Festuca arundinacea

<400> 21
 Met Gly Leu Leu Leu Phe Leu Gly Phe Leu Leu Pro Ala Ala Cys
 1 5 10 15
 Ala Ala Thr Ser Cys His Pro Asp Asp Leu Arg Ala Leu Arg Gly
 20 25 30
 Phe Ala Lys Asn Val Gly Gly Gly Gly Val Leu Leu Arg Thr Ala Trp
 35 40 45
 Ser Gly Thr Ser Cys Cys Val Trp Glu Gly Val Gly Cys Asn Gly Ala
 50 55 60
 Ser Gly Arg Ile Thr Thr Leu Trp Leu Pro Arg Arg Gly Leu Ala Gly
 65 70 75 80
 Thr Ile Thr Gly Ala Ser Leu Ala Gly Leu Ala Arg Leu Glu Ser Leu
 85 90 95
 Asn Leu Ala Asn Asn Arg Leu Val Gly Thr Ile Pro Ser Trp Ile Gly
 100 105 110
 Glu Leu Asp His Leu Leu Tyr Leu Asp Leu Ser His Asn Ser Leu Val
 115 120 125
 Gly Glu Leu Pro Asn Arg Leu Gln Ile Arg Leu Lys Gly Leu Thr Thr
 130 135 140
 Thr Gly His Leu Leu Gly Met Ala Phe Thr Asn Met Pro Leu Asp Val
 145 150 155 160
 Lys Arg Asn Arg Arg Thr Leu Ala Ile Gln Pro Asn Thr Ile Ser Gly
 165 170 175
 Thr Asn Asn Leu Val Leu Ser Gly Arg Asn Asn Val Val Ser Gly Asn
 180 185 190
 Asp Asn Thr Val Ile Ser Glu Asn Asn Thr Val Ser Gly Ser Phe
 195 200 205
 Asn Thr Val Ile Thr Gly Ser Asp Asn Val Leu Thr Gly Ser Asn His
 210 215 220
 Val Val Ser Gly Arg Ser His Ile Val Thr Asp Asn Asn Ser Val
 225 230 235 240
 Ser Gly Asp Asp Asn Asn Val Ser Gly Ser Phe His Lys Val Ser Gly
 245 250 255
 Ser His Asn Thr Val Ser Gly Ser Asn Thr Val Ser Gly Arg Asn
 260 265 270
 His Val Val Ser Gly Ser Asn Lys Ile Val Thr Gly Gly 285

<210> 22
 <211> 254
 <212> PRT

<213> Lolium perenne

<400> 22

Met Ala Lys Cys Leu Met Leu Leu Leu Ser Phe Ala Phe Leu Leu Ser
 1 5 10 15
 Val Ala Gly Thr Ala Thr Pro Cys His Arg Asp Asp Leu Arg
 20 25 30
 Ala Leu Arg Gly Phe Ala Glu Asn Leu Gly Gly Gly Gly Ala Ile Ser
 35 40 45
 Leu Arg Ala Ala Trp Ser Gly Ala Ser Cys Cys Asp Trp Glu Gly Val
 50 55 60
 Gly Cys Asp Gly Ala Ser Gly Arg Val Thr Ala Leu Trp Leu Pro Arg
 65 70 75 80
 Ser Gly Leu Thr Gly Pro Ile Pro Ser Trp Ile Cys Gln Leu His His
 85 90 95
 Leu Arg Tyr Leu Asp Leu Ser Gly Asn Ala Leu Val Gly Glu Val Pro
 100 105 110
 Lys Asn Leu Gln Val Gln Leu Lys Gly Ile Thr Asn Met Pro Leu His
 115 120 125
 Val Met Arg Asn Arg Arg Ser Leu Asp Glu Gln Pro Asn Thr Ile Ser
 130 135 140
 Gly Ser Asn Asn Thr Val Arg Ser Gly Ser Lys Asn Val Leu Ala Gly
 145 150 155 160
 Asn Asp Asn Thr Val Ile Ser Gly Asp Asn Asn Ser Val Ser Gly Ser
 165 170 175
 Asn Asn Thr Val Val Ser Gly Asn Asp Asn Thr Val Thr Gly Ser Asn
 180 185 190
 His Val Val Ser Gly Thr Asn His Ile Val Thr Asp Asn Asn Asn
 195 200 205
 Val Ser Gly Asn Asp Asn Asn Val Ser Gly Ser Phe His Thr Val Ser
 210 215 220
 Gly Gly His Asn Thr Val Ser Gly Ser Asn Asn Thr Val Ser Gly Ser
 225 230 235 240
 Asn His Val Val Ser Gly Ser Asn Lys Val Val Thr Asp Ala
 245 250

<210> 23

<211> 262

<212> PRT

<213> Festuca arundinacea

<400> 23

Met Ala Lys Cys Leu Met Leu Leu Leu Ser Phe Ala Phe Leu Leu Ser
 1 5 10 15
 Ala Ala Gly Thr Ala Thr Ala Thr Pro Cys His Arg Asp Asp Leu Arg
 20 25 30
 Ala Leu Arg Gly Phe Ala Glu Asn Leu Gly Gly Gly Gly Ala Leu Ser
 35 40 45
 Leu Arg Ala Ala Trp Ser Gly Ala Ser Cys Cys Asp Trp Glu Gly Val
 50 55 60
 Gly Cys Asp Gly Ala Ser Gly Arg Val Thr Ala Leu Trp Leu Pro Arg
 65 70 75 80
 Ser Gly Leu Thr Gly Pro Ile Pro Ser Trp Ile Cys Gln Leu His His
 85 90 95
 Leu Arg Tyr Leu Asp Leu Ser Gly Asn Ala Leu Val Gly Glu Val Pro
 100 105 110
 Lys Asn Leu Gln Val Gln Leu Lys Gly Leu Thr Ala Ala Gly Arg Ser
 115 120 125
 Gly Phe Thr Asn Met Pro Leu His Val Met Arg Asn Arg Arg Ser Leu
 130 135 140
 Asp Glu Gln Pro Asn Thr Ile Ser Gly Ser Asn Asn Thr Val Arg Ser
 145 150 155 160
 Gly Ser Lys Asn Val Val Ala Gly Asn Asp Asn Thr Val Ile Ser Gly
 165 170 175

Asp Asn Asn Ser Val Ser Gly Ser Asn Asn Thr Val Val Ser Gly Ser
 180 185 190
 Asp Asn Thr Val Thr Gly Ser Asn His Val Val Ser Gly Thr Asn His
 195 200 205
 Ile Val Thr Asp Asn Asn Asn Val Ser Gly Asn Asp Asn Asn Val
 210 215 220
 Ser Gly Ser Phe His Thr Val Ser Gly Gly His Asn Thr Val Ser Gly
 225 230 235 240
 Ser Asn Asn Thr Val Ser Gly Ser Asn His Val Val Ser Gly Ser Asn
 245 250 255
 Lys Val Val Thr Asp Ala

.260

<210> 24
 <211> 256
 <212> PRT
 <213> Lolium perenne

<400> 24
 Met Ala Lys Cys Leu Met Leu Leu Leu Ser Phe Ala Phe Leu Leu Ser
 1 5 10 15
 Ala Ala Gly Thr Ala Thr Ala Thr Pro Cys His Arg Asp Asp
 20 25 30
 Leu Arg Ala Leu Arg Gly Phe Ala Glu Asn Leu Gly Gly Gly Ala
 35 40 45
 Leu Ser Leu Arg Ala Ala Trp Ser Gly Ala Ser Cys Cys Asp Trp Glu
 50 55 60
 Gly Val Gly Cys Asp Gly Ala Ser Gly Arg Val Thr Ala Leu Trp Leu
 65 70 75 80
 Pro Arg Ser Gly Leu Thr Gly Pro Ile Pro Ser Trp Ile Phe Gln Leu
 85 90 95
 His His Leu Arg Tyr Leu Asp Leu Ser Gly Asn Ala Leu Val Gly Glu
 100 105 110
 Val Pro Lys Asn Leu Gln Val Gln Leu Lys Gly Ile Thr Asn Met Pro
 115 120 125
 Leu His Val Met Arg Asn Arg Arg Ser Leu Asp Glu Gln Pro Asn Thr
 130 135 140
 Ile Ser Gly Ser Asn Asn Thr Val Arg Ser Gly Ser Lys Asn Val Leu
 145 150 155 160
 Ala Gly Asn Asp Asn Thr Val Ile Ser Gly Asp Asn Asn Ser Val Ser
 165 170 175
 Gly Ser Asn Asn Thr Val Val Ser Gly Asn Asp Asn Thr Val Thr Gly
 180 185 190
 Ser Asn His Val Val Ser Gly Thr Asn His Ile Val Thr Asp Asn Asn
 195 200 205
 Asn Asn Val Ser Gly Asn Asp Asn Asn Val Ser Gly Ser Phe His Thr
 210 215 220
 Val Ser Gly Gly His Asn Thr Val Ser Gly Ser Asn Asn Thr Val Ser
 225 230 235 240
 Gly Ser Asn His Val Val Ser Gly Ser Asn Lys Val Val Thr Asp Ala
 245 250 255

<210> 25
 <211> 1083
 <212> DNA
 <213> Lolium perenne

<400> 25
 acttgcatc caaaaagggt tcttgcatcac acgtatttag aacaccagaa cttaatccat 60
 ggcgaaatgt tggctgctgc tgctcttctt ggtgttcctc ttgctggcca tgagcgcgac 120
 gtcgtgccac ctggatgacc tccgcgcgct gcggggcctt gtcgggaacc tcaatggcgg 180
 ggggtgccctt ctccgtggaa catggtctgg ctctcatgc tgcgattggg aaggtgtggg 240
 ctgcgatggt acaagcggcc gcgtcacggc gttgcggcct ccgattagcc tcgaggactg 300

cggtaagctc	aagtcgctca	accttgccaa	cgaaagattg	gttggcacca	tcccgtcgtg	360
gattgggtgag	cttgaccacc	attgctactt	ggttctctcg	gataattcat	tgggttggtaa	420
ggcaccacaat	agtttgcaca	atagtttgca	gataagactc	aagggcctcg	ccaccgctgg	480
tcgttcacta	ggatatggctt	tcgctaacat	gccattgcat	gtgaagggga	accgaagaac	540
cctcgacgaa	caaacaaata	caatacatgg	gaccaacaac	actgttagat	ctgggaacga	600
caatgctgtt	tctgggaacg	acaacactgt	catatgtggg	aacaacaaca	ctgtgtctgg	660
gagcaacaac	accattgcat	ctggcagtga	caatatcgta	actggcagca	accatattgt	720
atgtgggacc	aaacatatca	taactgataa	caacaatgac	gtatccggca	atgataataa	780
tgtatctggg	agcttccata	ctgtatccgg	gagccacaat	actgtatctg	gaagtaacaa	840
cactgtatct	ggaagcaacc	atgtcgtatc	tggaagcaac	aaagtcgtga	caggagatga	900
atgatttgtc	aggggattgc	ttccatcttt	cctaaaggag	cttcaccct	agtccaagtt	960
cgggtgcagct	cacaatcact	tggtagggac	aatcgagtta	tgtaacttca	tggatatagc	1020
atcattctcc	ctgtttaaat	atactttcct	gaaaatatct	tacataaatg	ctgaaaaaaa	1080
aaa						1083

<210> 26
 <211> 281
 <212> PRT
 <213> Lolium perenne

<400> 26
 Met Ala Lys Cys Trp Leu Leu Leu Leu Phe Leu Val Phe Leu Leu Leu
 1 5 10 15
 Ala Met Ser Ala Thr Ser Cys His Leu Asp Asp Leu Arg Ala Leu Arg
 20 25 30
 Gly Phe Val Gly Asn Leu Asn Gly Gly Gly Ala Leu Leu Arg Gly Thr
 35 40 45
 Trp Ser Gly Ser Ser Cys Cys Asp Trp Glu Gly Val Gly Cys Asp Gly
 50 55 60
 Thr Ser Gly Arg Val Thr Ala Leu Arg Leu Pro Ile Ser Leu Glu Asp
 65 70 75 80
 Cys Gly Lys Leu Lys Ser Leu Asn Leu Ala Asn Glu Arg Leu Val Gly
 85 90 95
 Thr Ile Pro Ser Trp Ile Gly Glu Leu Asp His His Cys Tyr Leu Val
 100 105 110
 Leu Ser Asp Asn Ser Leu Val Gly Lys Ala Pro Asn Ser Leu His Asn
 115 120 125
 Ser Leu Gln Ile Arg Leu Lys Gly Leu Ala Thr Ala Gly Arg Ser Leu
 130 135 140
 Gly Met Ala Phe Ala Asn Met Pro Leu His Val Lys Gly Asn Arg Arg
 145 150 155 160
 Thr Leu Asp Glu Gln Thr Asn Thr Ile His Gly Thr Asn Asn Thr Val
 165 170 175
 Arg Ser Gly Asn Asp Asn Ala Val Ser Gly Asn Asp Asn Thr Val Ile
 180 185 190
 Cys Gly Asn Asn Asn Thr Val Ser Gly Ser Asn Asn Thr Ile Ala Ser
 195 200 205
 Gly Ser Asp Asn Ile Val Thr Gly Ser Asn His Ile Val Cys Gly Thr
 210 215 220
 Lys His Ile Ile Thr Asp Asn Asn Asn Asp Val Ser Gly Asn Asp Asn
 225 230 235 240
 Asn Val Ser Gly Ser Phe His Thr Val Ser Gly Ser His Asn Thr Val
 245 250 255
 Ser Gly Ser Asn Asn Thr Val Ser Gly Ser Asn His Val Val Ser Gly
 260 265 270
 Ser Asn Lys Val Val Thr Gly Asp Glu
 275 280

<210> 27
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Made in the lab
 <400> 27
 gaattcggta ccccatcaac 20
 <210> 28
 <211> 20
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 28
 gcatgtgagt gaacgcctta 20
 <210> 29
 <211> 20
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 29
 gaattcggta ccccatcaac 20
 <210> 30
 <211> 20
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 30
 gtgatcaagc tcaccaatcg 20
 <210> 31
 <211> 20
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 31
 gaattcggta ccccatcaac 20
 <210> 32
 <211> 20
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 32
 aggatgctcc tgtgatggtc 20
 <210> 33
 <211> 20
 <212> DNA
 <213> Artificial sequence

<220>
 <223> Made in the lab
 <400> 33
 gaattcggta ccccatcaac 20
 <210> 34
 <211> 20
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 34
 tgggtgaagct gacaaatcca 20
 <210> 35
 <211> 25
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 35
 gaattcggcg tcgtgccacc ctgat 25
 <210> 36
 <211> 33
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 36
 tctagaggat ccttaacctc ctgtcacgca ttt 33
 <210> 37
 <211> 28
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 37
 gaattcggac gaagaccaca atacaata 28
 <210> 38
 <211> 33
 <212> DNA
 <213> Artificial sequence
 <220>
 <223> Made in the lab
 <400> 38
 tctagaggat ccttaacctc ctgtcacgca ttt 33
 <210> 39
 <211> 22

<212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in the lab
 <400> 39
 gaattcggca acgtcgtggt cg 22
 <210> 40
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in the lab
 <400> 40
 tctagaggat ccttaaccat ctgttacgac ttt 33
 <210> 41
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in the lab
 <400> 41
 gaattcggcg acgtcgtgcc acctg 25
 <210> 42
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in the lab
 <400> 42
 tctagaggat cctcattcat ctctgtcac gag 33
 <210> 43
 <211> 22
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in the lab
 <400> 43
 gaattcgacg ccatgccacc gc 22
 <210> 44
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Made in the lab
 <400> 44
 tctagaggat ccttaagcgt ctgtcacgac ttt 33

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
18 March 2004 (18.03.2004)

PCT

(10) International Publication Number
WO 2004/022700 A3

- (51) International Patent Classification⁷: **C12N 15/29**, C07K 14/415, A01H 1/00 (74) Agent: **BALDWIN SHELSTON WATERS**; P.O. Box 852, Wellington (NZ).
- (21) International Application Number: PCT/NZ2003/000199 (81) Designated States (*national*): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT (utility model), PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 9 September 2003 (09.09.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/409,557 9 September 2002 (09.09.2002) US (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicants (*for all designated States except US*): **GENESIS RESEARCH AND DEVELOPMENT CORPORATION LIMITED** [NZ/NZ]; 1 Fox Street, Parnell, Auckland (NZ). **WRIGHTSON SEEDS LIMITED** [NZ/NZ]; Wrightson House, 14 Hartham Place, Porirua (NZ).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **DEMMEER, Jeroen** [NL/NZ]; 317 Albany Highway, Albany, Auckland (NZ). **SHENK, Michael, Andrew** [US/NZ]; 83 a Te Awe Awe Street, Hokowhitu, Palmerston North (NZ). **HALL, Claire** [GB/NZ]; 3/253 Kapa Road, Mission Bay, Auckland (NZ). **FISH, Steven, A.** [GB/NZ]; 48 Gladstone Road, Parnell, Auckland (NZ).
- Published:**
— with international search report
- (88) Date of publication of the international search report: 6 May 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: ANTIFREEZE PROTEINS ISOLATED FROM FORAGE GRASSES AND METHODS FOR THEIR USE

(57) Abstract: Isolated polynucleotides encoding antifreeze polypeptides are provided, together with expression vectors and host cells comprising such isolated polynucleotides. Methods for the use of such polynucleotides and polypeptides are also provided.



WO 2004/022700 A3

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NZ2003/000199

A. CLASSIFICATION OF SUBJECT MATTER					
Int. Cl. ⁷ : C12N/ 15/29; C07K 14/415; A01H 1/00					
According to International Patent Classification (IPC) or to both national classification and IPC					
B. FIELDS SEARCHED					
Minimum documentation searched (classification system followed by classification symbols) See Electronic Databases					
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched See Electronic databases					
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Dgene, NR protein(NCBI) and NR nucleic (NCBI) databases: Sequence Id Nos.: 1-8, 10 and 12, 13-20, 22 and 24					
C. DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.			
X	GenBank Acc No AJ277399. Lolium perenne partial mRNA for ice recrystallisation inhibition protein. Sidebottom CM. 2000	All			
X	GenPept Acc No CAB87814. Ice recrystallisation inhibition protein [Lolium perenne]. Sidebottom CM. 2000	All			
X	WO 1999/006565 A2 (ICE BIOTECH INC). 11 February 1999	12-25			
X	WO 2001/083534 A1 (UNILEVER PLC) 8 November 2001	26-28			
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex					
<table style="width: 100%; border: none;"> <tr> <td style="width: 33%; vertical-align: top;"> <p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="width: 33%; vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p> </td> <td style="width: 33%;"></td> </tr> </table>			<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>	
<p>* Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier application or patent but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p>	<p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>				
Date of the actual completion of the international search 14 January 2004		Date of mailing of the international search report 23 JAN 2004			
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer Gillian Allen Telephone No : (02) 6283 2266			

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ2003/000199

Box I Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos :
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos :
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box II Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

The ISA found 13 separate inventions.

See Supplemental Box II for details

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by Sequence Id Nos: 1-8, 10 and 13-20, 22 and 24.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ2003/000199

Supplemental Box II

(To be used when the space in any of Boxes I to VIII is not sufficient)

Continuation of Box No: II

Lack Of Unity

It is a requirement of the PCT, under rule 13 of the PCT, that the claims shall define a single invention, where all claims are linked by a common special technical feature that defines the invention. A special technical feature is defined as being that feature that provides the advance over the prior art. The present claims do not conform to this requirement.

The ISA has identified 13 separate inventions.

The present claims are directed to 13 proteins and their encoding nucleic acids that have been isolated from either perennial ryegrass or tall fescue, whose common feature is that they are antifreeze proteins. Plant antifreeze proteins, including those from grasses, are known. Thus the common feature of plant, or more specifically grass, antifreeze protein activity cannot be a special technical feature that unites the proteins of the claims. Thus each protein and its encoding nucleic acid of the claims defines a single invention.

As a service to the Applicants, 10 amino acid sequences, and their encoding polynucleotide sequences, as specified by the applicants, have been searched.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/NZ2003/000199

Information on patent family members

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report	Patent Family Member
WO 01/83534	AU4653301 BR0110394 CA2407738 CN1439019 EP1276763 GB0010314D
WO 99/06565	AU 86206/98 CN 1273604 EP 1002101

END OF ANNEX